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ABSTRACT 
 
AMY CATHERINE WOLLISH:  Contributions of the host immune response to control and 
protection upon infection with a neurovirulent alphavirus. 
(Under the direction of Mark Heise, Ph.D.) 
 
 Alphaviruses are mosquito-borne viruses within the family Togaviridae.  These 
positive-sense RNA viruses pose a significant human and equine public health threat due to 
their ability to cause explosive epidemics of infectious rheumatic disease and 
encephalitis.  The AR86 strain of Sindbis virus (SINV, infectious clone: S300) is 
neurovirulent in adult mice.  A critical viral genetic determinant of neurovirulence within 
S300 is a Threonine at nonstructural protein (nsP) 1 position 538, whereby introduction of an 
Isoleucine at this locus is attenuating in vivo.  The mutant nsP1 T538I virus induces more 
type I interferon (IFN) and fails to efficiently block type I and II IFN signaling as compared 
to S300 virus. Importantly, nsP1 T538I replicates as well as S300 virus at early times post-
infection within the central nervous system (CNS) of infected mice, however at late times 
post-infection, nsP1 T538I is more efficiently controlled and cleared.  In this work, we 
investigated the components of the host innate and adaptive immune system that modulate 
AR86-induced neurologic disease.  
Herein, we identify the IPS-1 pathway of intracellular RNA sensing as mediating 
protection from nsP1 T538I disease and driving viral clearance.  Furthermore, we 
demonstrate that the TRIF-dependent pathway, which is essential for TLR3 and one pathway 
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of TLR4 signaling, is moderately protective against the AR86 strain of SINV.  IPS-1 and 
TRIF are adaptor molecules essential for signal transduction that results in the upregulation 
of interferon stimulated genes (ISGs), which in turn exert virus-specific antiviral activity. 
These studies reveal that two ISGs, IFIT1 and IFIT2, inhibit nsP1 T538I replication within 
IFN-β primed murine cells.  
We further demonstrate protective roles for T and B cells during nsP1 T538I 
infection, while the viral control conferred by T and B cells did not require their intrinsic 
ability to respond to type I IFN.  Finally, these studies demonstrate contradictory phenotypes 
during AR86 infection of IFN-gamma receptor and cytokine knockout mice, thereby 
challenging the paradigm of IFN-gamma-mediated noncytolytic clearance from neurons.  In 
sum, these studies identify key innate immune sensing pathways that modulate alphavirus 
neurovirulence and also refine our understanding of the role of adaptive immunity during 
clearance of a neurovirulent alphavirus.   
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CHAPTER ONE: 
INTRODUCTION 
 
1.1 Alphavirus background 
 
Alphaviruses are small, enveloped viruses with a positive-sense single stranded RNA 
genome and belong to the family Togaviridae.   Alphaviruses have a nearly worldwide 
distribution and cycle in nature between an arthropod vector (mainly mosquito) and a 
vertebrate host, such as a small mammal or bird.   However, these viruses can acquire 
mutations resulting in an increased mosquito host range and/or spillover infection of equines 
and humans.  Thereby, alphaviruses can cause epidemics, and represent a significant public 
health threat.  Human infection by pathogenic Old World alphaviruses can cause long-lasting 
arthritis and myositis, while human and equine infection by pathogenic New World 
alphaviruses can cause encephalitis with a threat of mortality.  Currently, no specific vaccine 
or antiviral therapy exists to prevent or treat alphavirus infection.   
This dissertation focuses primarily on the neurologic disease caused by alphaviruses, 
and we define the host pathways necessary for eliciting a protective immune response to 
infection with a neurovirulent Sindbis virus (SINV).  This chapter provides an overview of 
alphavirus biology and the distinct SINV mouse models.  We further discuss the type I and II 
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interferon response, the immune system within the central nervous system (CNS), and known 
alphavirus-host interactions.   
 
Alphavirus structure and genome organization 
Alphaviruses have a single-stranded positive-sense RNA genome of approximately 
11.7 Kb in length.  The genome is flanked by a 5’ cap and a 3’ poly-adenylated tail, and 
contains two open-reading frames.  Expression of the nonstructural genes is under the control 
of a 49S promoter, while the structural genes are regulated by an internal 26S promoter.  The 
genomic RNA is enclosed by 240 copies of the capsid protein arranged in icosohedral 
symmetry.  The nucleocapsid is surrounded by envelope glycoproteins, E1 and E2 that are 
embedded within a lipid bilayer derived from the host cell plasma membrane.  E1 and E2 
form 80 trimeric spikes with T = 4 quasi-symmetry (295).   
 
Evolution of alphaviruses 
Alphaviruses are arboviruses, and thus are transmitted by arthropod vectors (e.g. 
mosquitoes).  The dual-host life cycle of alphaviruses mandates that these viruses maintain 
fitness in vector and reservoir hosts with markedly different microenvironments and selective 
pressures.  Yet, the wide distribution of alphaviruses demonstrates that these viruses are very 
capable of usurping the distinct host machinery to replicate and spread successfully. 
The alphavirus genus includes 29 recognized species (75).  Both serological cross-
reactivity based classifications and full-length genome analyses partition alphaviruses into 
four subgroups:  the Semliki Forest complex (which includes Ross River virus (RRV), 
chikungunya virus (CHIKV), and Semliki Forest virus (SFV), the Western Equine 
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Encephalitis (WEE) complex (which includes SINV), the Venezuelan Equine Encephalitis 
(VEE) complex, and the Eastern Equine Encephalitis (EEE) complex (38, 81).  Even the 
most recent comprehensive alphavirus phylogenetic analysis (81) cannot distinguish between 
a New World or an Old World origin of alphaviruses.  However, it is clear that numerous 
reintroductions occurred after the initial introduction in one of the two hemispheres (81, 
246).  Most interestingly, these analyses suggest that alphaviruses may have emerged in the 
Pacific Ocean in either terrestrial or marine hosts, and likely were spread via the mosquito.  
This hypothesis was, in large part, derived from the sequencing and subsequent placement of 
the aquatic alphaviruses, salmon pancreatic disease virus and Southern elephant seal virus, at 
basal positions in the phylogenetic tree (81).   
Viruses within the SINV clade of the WEE complex (hereafter referred to as SINV-
like viruses) include Ockelbo virus, Babanki (BAB) virus, and Whataroa (WHA) virus, all of 
which are found in the Old World.  The only New World SINV-like virus is Aura virus, 
found in Brazil.  Viruses within the WEE clade of the WEE complex are likely recombinant 
viruses wherein E1 and E2 are derived from a SINV-like ancestor while the nonstructural 
genes, capsid, and part of the 3’ nontranslated region are derived from EEE virus (116, 246, 
330).  The fact that SINV (Old World) is more closely related to WEE (New World) than to 
Aura virus (New World) suggests that Aura virus and the SINV ancestor diverged in the New 
World prior to the transfer of SINV to the Old World (256).   
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1.2 Alphavirus life-cycle 
 
The elusive alphavirus receptor 
Alphaviruses infect a broad host range and numerous cell types within each host, 
including dendritic cells (DCs), muscle cells, connective tissues, neurons, and fibroblasts.  
Alphaviruses enter the host cell via receptor-mediated endocytosis at the plasma membrane, 
a process that is discussed in detail below.  Due to the wide array of infected cell types, mode 
of entry, and diverse host range, the alphavirus receptor must be evolutionarily conserved 
and nearly ubiquitously expressed at the plasma membrane. 
Despite an immense effort, the identification of a true alphavirus receptor was not 
made until 2011.  This delay was in part due to the confounding tendency of alphaviruses to 
acquire cell culture adaptations that confer the ability to interact with the glycosaminoglycan, 
heparan sulfate (158).  Whereas heparan sulfate does not mediate entry of most wildtype 
alphaviruses, certain wildtype EEE strains interact with heparan sulfate (discussed in detail in 
section 1.4) (158).       
Klimstra et al. has shown that the C-type lectins, DC-specific ICAM-3 grabbing non-
integrin (DC-SIGN) and liver/lymph node-specific ICAM-3 grabbing non-integrin (L-SIGN), 
act as coreceptors for mosquito-derived SINVs on DCs (156).   C-type lectins can bind 
carbohydrate structures via a carbohydrate recognition domain, and thus the specificity of 
mosquito-derived and not mammalian-derived SINV to bind DC-SIGN and L-SIGN suggests 
that glycosylation of viral glycoproteins may alter host receptor interactions.  Furthermore, 
mosquito-derived RRV, that contains simple glycans has a higher infection efficiency in DCs 
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than mammalian-derived RRV containing complex glycans (156, 283).  Finally, the laminin 
receptor may serve as an alphavirus attachment factor and thus enhance infection (326).   
  Only recently has the SINV receptor been identified as being Natural Resistance-
Associated Macrophage Protein (NRAMP) (254).  NRAMPs are highly conserved proteins 
that have 12 transmembrane domains involved in transport of heavy metal ions such as iron 
across cell membranes (8, 226).  Importantly, humans have 2 NRAMP genes: NRAMP1, 
which is expressed only on the membrane of late endosomes and lysosomes of macrophages, 
dendritic cells (113, 279), in granules of polymorphonuclear leukocytes (39), and in neurons 
(73), while NRAMP2 is ubiquitously expressed at the plasma membrane and in endosomes 
(226).  In Drosophila cells, dNRAMP is required for SINV binding and infection, and in 
mammalian cells, NRAMP2 is required for SINV binding and infection.  Somewhat 
surprisingly, Ross River virus (RRV) entry is independent of NRAMP, and whether NRAMP 
or other receptors mediate entry of other alphaviruses has yet to be determined.  Interestingly, 
NRAMP2 is sensitive to the effects of iron, whereby both NRAMP2 mRNA and protein are 
degraded when iron levels are high (80, 191, 203).  Treatment of insect or mammalian cells 
with iron significantly reduced SINV infection (254), thereby suggesting that high amounts 
of iron may affect the fitness of SINV in nature.  Further studies are needed to clarify 
whether NRAMP1 has a role in alphavirus entry or fusion with the endosomal membrane.     
 
Entry 
The entry of alphaviruses begins with receptor binding at the plasma membrane and 
proceeds via clathrin-mediated endocytosis (150, 295).  Next, alphaviruses are internalized 
and clathrin-coated vesicles fuse with the endosome.  Within the endosome, a pH of <6 
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induces a conformational change and release of E1 from the E1-E2 heterodimers.  E1 
homotrimers then bind the target vesicle membrane by inserting the hydrophobic fusion 
peptide and forming pores in the cell and viral membranes (176, 227, 274, 294, 295).  While 
receptor-mediated, clathrin-dependent endocytosis and fusion with endosomes is likely the 
predominant entry route, there is evidence that alphaviruses can enter via a clathrin-
independent pathway (43, 53, 125, 235, 325).  Cholesterol is necessary for fusion of SINV, 
CHIKV, and SFV; however VEEV fusion does not require cholesterol (18, 162).  
 
Protein translation and processing  
Once the alphavirus particle reaches the cytoplasm it disassembles and releases the 
genomic RNA, which then associates with ribosomes and can be directly translated to yield 
the nsP polyprotein P1234, along with the P123 polyprotein (98).   Shortly thereafter, P1234 
is cleaved by the nsP2 papain-like cysteine protease in cis or trans between nsP3 and nsP4 to 
produce P123 and nsP4 (59, 303).  P123 and P4 together drive the synthesis of negative-
strand viral RNA, which occurs up until 3-4 hpi, at which time nsP1 is released by cis 
cleavage from the P123 polyprotein, and finally the P23 intermediate (at the 2/3 site) is 
cleaved in trans (61, 180, 286, 295).   The intermediate P23, along with free nsP1 and nsP4, 
comprise a replication complex that can drive negative-strand synthesis, albeit less efficiently 
than P123 and nsP4, in addition to positive-strand synthesis, but not 26S RNA synthesis (61, 
178).  Once the 2/3 site is cleaved, negative-sense synthesis is terminated, and positive-sense 
and 26S RNA synthesis ensues.   Most alphaviruses encode a leaky opal stop codon (UGA) 
near the 3’ end of nsP3 (AR86 encodes a sense codon that is a virulence determinant), which 
when present leads to the translation of P1234 at 5-20% the levels of P123 (186, 221, 271, 
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295).  Therefore the nsP4 protein is produced at significantly lower levels than P123.  In 
addition, nsP4 protein levels are restricted by the presence of a destabilizing tyrosine at the 
N-terminus of nsP4 that initiates degradation by the N-end rule pathway of any free nsP4 that 
is not present within replication complexes (60).   
The structural proteins are translated late during infection as a second polyprotein, 
and include capsid, the E1 and E2 envelope proteins, and the smaller proteins 6K and E3 (84, 
295).  Capsid protein cleaves itself from the structural polyprotein (233, 335).  E3 contains a 
signal sequence that directs the remaining envelope polyprotein precursor E3-E2-6K-E1 into 
the lumen of the endoplasmic reticulum (ER), where host signalases process the N- and C-
terminus of the 6K peptide to generate E3E2 (also referred to as PE2), 6K, and E1. 
Subsequently, E3E2 and E1 form heterodimers in the early Golgi, traffic to the plasma 
membrane, and E3E2 is cleaved by a host furin-like protease to release mature E2 and E3 
(58, 266).  Capsid oligomerizes and recognizes a packaging signal within either nsP1 or nsP2 
to direct encapsidation of the viral genomic RNA into the virion.  Capsid interacts with E2 to 
facilitate budding from the plasma membrane.  The budded virion retains a lipid membrane 
from the host cell plasma membrane.   
 
The nonstructural proteins 
The nsP1 protein contains guanine-7-methyltransferase and guanylyl transferase 
activities, both essential for capping and methylation of viral genomic and 26S RNA species 
(4, 214).  In addition, nsP1 tethers the replication complex to the plasma membranes and to 
the outer surface of endosomes (240).  The nsP2 protein contains RNA and nucleoside 
triphosphatase activity (116, 117), helicase activity in the N-terminal region, and papain-like 
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cysteine protease activity in the N-terminal region (100, 252, 319).  While nsP3 is essential 
for replication, only recently was it shown to contain a conserved proline-rich Src homology-
3 (SH3) domain that is essential for interactions with amphiphysin-1 and Bin1/amphiphysin-
2, two cellular adaptor proteins involved in endocytosis and membrane trafficking (225).  
Mutations within the nsP3 SH3 binding site resulted in reduced viral replication in vitro and 
decreased pathogenicity in mice (225).  The nsP4 protein serves as the RNA-dependent 
RNA-polymerase (RdRp) (115), and possesses adenylyltransferase activity, with both 
enzymatic functions attributed to a GDD amino acid motif within the C-terminus (308).   
 
The structural proteins 
To facilitate assembly of the virion, the capsid protein binds viral genomic RNA and 
glycoproteins (233, 234, 334).   The function of E3 is not defined and only certain 
alphaviruses incorporate E3 into the virion, with SINV not being one of those viruses (287).  
The E2 protein mediates receptor binding via 30 C-terminal amino acid residues (190, 292), 
while the E1 protein contains a fusion peptide that facilitates fusion with the host cell (22, 
230).  Lastly, the palmitoylated 6K protein may be involved in transport to viral assembly 
sites at the plasma membrane (90, 197).   
 
1.3 Pathogenic alphaviruses and epidemics 
 
Symptoms 
Infection with alphaviruses is oftentimes asymptomatic, however pathogenic 
alphaviruses cause acute, febrile illness in humans and domestic animals that can progress to 
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either encephalitis, as is the case for the New World viruses or arthralgia and arthritis, as is 
the case for the Old World viruses (107).   Arthralgia occurs mainly in small joints and more 
often in adults than in children.  In severe cases, joints can become swollen and arthralgia 
may persist for weeks or months.    
The alphaviruses associated with encephalitis are WEEV, VEEV, and EEEV, and less 
commonly RRV and CHIKV (reviewed in (348)).  WEEV and VEEV cause a febrile disease 
that only rarely progresses to encephalitis, however in equines encephalitis is common and 
the mortality rate after VEEV infection is greater than 50% (324).  WEEV and VEEV have a 
human case fatality rate of 3-7% and 0.5-1%, respectively (348).  VEEV has the capability to 
be transmitted by the aerosol route, and has been developed as a biological weapon in the 
United States and the Soviet Union.   
 Humans infected with the highly pathogenic North American EEEV experience 
fever, chills, myalgia, arthralgia, retro-ocular pain, headache, and decreased consciousness, 
whereas the very young often progress to neurologic symptoms in the absence of other 
symptoms (64).  EEEV causes neurologic disease, marked by paralysis, seizures, coma and 
death in 30-80% of infected humans, with long-term neurologic deficits reported in 35% of 
surviving individuals (103).    
 
Transmission 
Alphaviruses persist in nature in an enzootic cycle by replicating alternatively in a 
small mammal or bird and an arthropod.  An arthropod bites a viremic host, followed by 
amplification of the virus within the infected arthropod, and subsequent delivery to a new 
vertebrate host through salivary secretions.  Viral mutations have been linked to the ability of  
10 
 
alphaviruses to enter an epizootic transmission cycle, whereby an arthropod transmits the 
virus to a horse, human, or other large mammal (24, 25, 328).       
 
Alphavirus epidemics 
 Historically, there are multiple of examples of alphavirus crossover to human 
populations or spread to new regions.  Although endemic to Australia, RRV caused an 
outbreak in 1979, when it spread to the island of Fiji, American Samoa, and the Cook islands 
(1, 16, 257).  During this epidemic, ~500,000 humans were infected, with ~50,000 of them 
experiencing severe arthralgia, rash and fever (1, 16).  Patients infected with RRV report 
symptoms of acute fever, rash, myalgia, and arthralgia that can persist for upwards of 6 
months.  In 1995, an outbreak of VEEV occurred in Venezuela and Columbia that resulted in 
75,000-100,000 affected humans and a case fatality rate of 0.7% (44, 45, 331).  
The most recent alphavirus epidemic began with the re-emergence of CHIKV in 
Africa and Asia beginning in 2000, after a greater than 20 year absence of reported cases 
(177, 237, reviewed in (36)).  Then, in 2005-2006, an outbreak that included greater than 1.5 
million patients was reported in the Indian Ocean islands, followed by India.  Patients 
infected during this outbreak not only had the typical CHIKV symptoms of arthralgia and 
arthritis, but also central nervous system (CNS) manifestations and acute liver failure (23, 
290, 305).  The inevitability of long-distance spread via infected travelers along with the 
acquired ability of CHIKV to infect the Aedes albopictus mosquito species likely contributed 
to the emergence of CHIKV in northern Italy in 2007 (251).  CHIKV is especially dangerous 
because, unlike most alphaviruses, CHIKV can be maintained in an urban cycle, in which 
human-mosquito-human transmission occurs (reviewed in (329)).   
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SINV has the distinction of being the most widely distributed of all arboviruses, and 
has been isolated in Europe, the Middle East, Africa, India, Asia, Australia, New Zealand, 
and the Philippines, with a likelihood of having been present in the Western hemisphere 
(159).  SINVs use birds as their vertebrate hosts and the Culex mosquito species as vectors 
(196).  Interestingly, migratory bird patterns can serve to explain the genetic relatedness of 
SINV genotypes, thereby supporting the idea that birds drive the spread of SINV (196).  
Despite its near worldwide prevalence, SINV is documented as being the etiologic agent of 
outbreaks of rash and arthritis only in South Africa, Sweden (Ockelbo virus), Finland 
(Pogosta disease), and the Karelian part of Russia (Karelian fever) (31, 195, 211).  SINV 
does not undergo human-mosquito-human transmission, but rather outbreaks are thought to 
arise when strains that normally circulate in Culex or Culiseta spp. and birds gain the ability 
to infect human-feeding mosquitoes, such as Aedes spp. (159).   
  
1.4 The SINV mouse-model 
 
Isolation and selection histories 
Although SINV causes an arthritic and arthralgic disease in humans, the most 
relevant SINV model is one of acute encephalomyelitis in mice.  Multiple strains of SINV 
have been used to investigate pathogenesis and host-pathogen interactions.  The host 
mechanisms of protection, viral clearance, and disease exacerbation differ among SINV 
strains.  Therefore, the following description of SINV strains should serve to demonstrate the 
disparate origins, selection histories, and disease presentation in mice of the best-studied 
SINV strains.   
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The outcome of SINV infection in mice is dependent upon mouse age and strain, 
route of inoculation, and virus strain (105, 106, 171, 316).  As a group, all SINVs cause 
lethal disease in neonatal mice, marked by high levels of proinflammatory cytokines, and 
uncontrolled replication in the muscle, brain, and serum (157, 312, 313).  All SINVs, with 
the exception of strains AR86, NSV, and SVNI, are completely avirulent in adult mice, 
regardless of the dose or inoculation route.  However, of the three adult neurovirulent strains, 
SVNI is unique in that it is also neuro-invasive in adult mice.  The age-dependent resistance 
to neuro-invasion is not specific to SINV in mice, and has been reported for numerous 
neurotropic virus families including rhabdoviruses, reoviruses, bunyaviruses, and flaviviruses 
(reviewed in (229)).   
 
AR339 
The prototypic SINV strain is AR339, which was isolated from a pool of mosquitoes 
in the village of Sindbis, near Cairo, Egypt in 1952 (306).  AR339 (infectious clone TR339) 
has been further passaged to generate numerous cell culture and mouse-adapted strains.  
However, a consensus cDNA clone was generated in an effort to recreate a virus as close as 
possible to the original AR339 isolate (158).  TR339 is more virulent than its cell-culture 
adapted counterparts, the latter of which cause encephalitis in neonatal mice.   Neonatal mice 
that are infected peripherally with TR339 show uncontrolled replication in the periphery that 
results in a dysregulated hyper-production of pro-inflammatory cytokines, including type I 
IFN, TNF-α, IFN-γ, IL-12(p40), and IL-6 (157).  Neuro-invasion occurs during the late 
stages of disease, but in the absence of neurologic sequelae or CNS inflammation or damage.  
Histopathology and symptomology are characteristic of virus-induced systemic inflammatory 
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response syndrome (SIRS) (133).  Therefore, neonatal mice infected with TR339 most likely 
die from SIRS (313).   
To better understand the host mechanism of age-resistance to TR339, adult mice 
deficient in IFN-α/β receptor (Ifnar-/-), IFN-γ receptor (IFN-γ R-/-), or doubly deficient mice 
were infected.  Ifnar-/- displayed a rapid progression to death, while IFN-γ R-/- mice showed 
no disease signs and were indistinguishable from wt mice.  The double-knockout mice 
succumbed even more quickly than Ifnar-/- mice.  Both mouse strains that succumbed to 
TR339 infection exhibited increased viral tropism for macrophage-DC lineage cells that are 
not normally infected in wt mice.  Therefore, these results suggest that type I IFN is a critical 
component of age-dependent resistance, with IFN-γ having an accessory role (108).  A later 
study compared CNS gene expression during lethal neonatal infection with TR339 and 
avirulent 4-week old infection with TR339 by the i.c. route of infection.   Although most host 
inflammatory genes are up regulated in neonates infected with TR339 as compared to 
weanling mice, ISG12 was down regulated in neonates.  However, 100% lethality was 
observed in neonatal mice infected with the SINV expressing ISG12, and viral replication 
was unchanged by ISG12 expression (172).  Other studies have suggested that age-dependent 
resistance may be related to the resistance of adult neurons to apoptosis (reviewed in (109)).     
 
TR339:  heparan sulfate binding 
Certain laboratory-adapted strains derived from TR339 evolved cell culture 
adaptations that conferred heparan sulfate (HS) binding.  Although these mutations were 
advantageous in cell culture, Klimstra et al. demonstrated that these mutations attenuated the 
viruses in vivo, while simultaneously promoting encephalitis (158).  However, a more 
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comprehensive analysis demonstrated that HS-binding mutations are attenuated by the 
subcutaneous route, but are actually more virulent when delivered intracranially (i.c.).  
Ryman et al. postulated that this discrepancy reflected enhanced CNS-specific replication, 
and/or impaired peripheral replication of HS mutants (258).  Furthermore, sequence data 
from wild type isolates of circulating strains EEEV revealed the presence of HS-binding 
properties (92, 347).  Mutating the HS-binding site within EEEV decreased neurovirulence in 
vivo, but increased lymphoid tissue replication and cytokine and chemokine production (92).  
Therefore, HS binding may have relevance in nature, however further work is necessary to 
fully understand the selective pressures that drive HS binding and the resulting affects on in 
vivo virulence.     
 
NSV 
Neuro-adapted SINV (NSV) was derived from AR339 that was passaged an unknown 
number of times in cell culture, followed by 6 rounds of selection in neonatal and weanling 
mice (111).  Adult mice infected with NSV exhibit symptoms of neurologic disease, such as 
ruffled fur, hunched posture, and hind limb paralysis.  NSV infects almost exclusively 
neurons within the hippocampus, adjacent white matter, and cerebral cortex, where it causes 
significant neuronal cell death (153).  Approximately 80-100% of adult C57BL/6 mice die 
from NSV infection between 6 and 11 dpi (111, 138).  The most critical NSV neurovirulence 
determinant is a His amino acid at E2 position 55 (316).  However, a change from Glu to Lys 
at E2 position 70, which coincidently also confers HS binding, also increases neurovirulence 
in adult mice (258). 
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SVA/SVB and SVN/SVNI 
Two pairs of SINV variants (SVA and SVB) and  (SVN and SVNI) were derived by 
separate passages, but from a single virus isolated from a pool of culicine mosquitoes 
collected in southern Israel in 1983 (198).  SVN was generated after 15 alternating passages 
in suckling and weanling mouse brains and is neurovirulent.  To generate SVNI, an addition 
7 passages were performed in weanling mice, and SVNI is both neurovirulent and neuro-
invasive in adult mice (69, 161).  The neuro-invasive determinants within SVNI were 
mapped to the 5’ noncoding region (NCR) and the E2 position 190 (Met-190) (69, 161).  
SVA and SVB are early passage isolates that are neurotropic, but not neurovirulent, and SVB 
is nonlethal, but neuro-invasive.  The neuro-invasive determinant for SV was mapped to E2 
position 55 (Gln-55) (69, 161).  Of the four strains derived from the Israeli isolate, only 
SVNI is neurovirulent in adult rats (but not neuro-invasive), and this determinant was also 
mapped to the 5’ NCR (160).  While these viruses have not been extensively studied, they 
provide excellent tools, and the exclusive opportunity to study neuro-invasion of SINVs.   
 
AR86 
S.A.AR86 (hereafter referred to as AR86 or as the infectious clone S300) was 
isolated near Johannesburg, South Africa in 1954 from a pool of Culex spp. mosquitoes 
(333), followed by 60 rounds of alternate intracranial passage in neonatal and weanling mice, 
with very limited cell culture passage prior to generating an infectious clone (111, 291, 333).  
In 1963, Girdwood was isolated from a skin lesion of an infected, symptomatic patient in 
Johannesburg, South Africa (202).  An infectious clone of Girdwood (G100) was derived 
without mouse brain or cell culture selection (291, 297).   
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AR86 causes lethal neurologic disease in adult mice (291).   Mice exhibit signs of 
disease including weight loss, ruffled fur, hunched posture, hind-limb dysfunction, paralysis, 
and ultimately become moribund (122, 297).  Even after i.c. inoculation, the closely related 
G100 is avirulent in adult mice, although G100 replicates in the CNS equivalently to S300 at 
early times post-infection.  The host innate and adaptive immune pathways that modulate in 
vivo pathogenesis of AR86 and control of attenuated mutants of AR86 have not yet been 
published (with the exception of type I IFN), and are therefore the subject of this dissertation.  
However, extensive studies have characterized the AR86 genetic determinants of 
neurovirulence, and these results will be detailed in the following section.       
 
AR86 neurovirulence determinants 
Comparison of S300 with other sequenced SINVs showed that S300 encodes a Thr at 
nsP1 position 538, while Ile is consensus among other SINVs.  The nsP1 position 538 amino 
acid is positioned within the nsP1/2 cleavage domain at the P3 position.  An S300 virus was 
constructed that encoded an Ile at nsP1 538 (infectious clone S340, or nsP1 T538I are 
synonymous).  Adult 6-week-old CD-1 mice infected i.c. with S300 showed clinical signs of 
hind limb weakness, paresis, and paralysis, and death ensued 5-6 dpi.  The nsP1 T538I virus 
caused less severe disease and no mortality (122).  In addition, when a Thr is introduced at 
nsP1 position 538 of TR399 virus (avirulent in adult mice), this virus caused more severe 
disease signs and increased mortality as compared to the TR339 parental strain (122).  In 
addition to its role in neurovirulence, the nsP1 T538I mutation accelerated polyprotein 
processing and showed earlier production of viral 26S RNA (122).  Finally, the nsP1 T538I 
mutant virus induces significantly greater type I IFN both in vitro and in the serum of 
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infected animals (56), and a Thr at nsP1 position 538 is both necessary and sufficient to 
block Jak/STAT signaling in response to type I or II IFN (289).   
Sequence analysis and comparison between S300 and G100 revealed 20 single amino 
acid differences, in addition to an 18 amino acid deletion within nsP3 (291, 297).  Because 
S300 causes lethal neurologic disease and G100 is avirulent, these viruses were ideal tools to 
investigate the genetic determinants of neurologic disease.  Chimeric S300 and Girdwood 
viruses were constructed, and infected by the i.c. route into adult outbred CD-1 mice to 
determine virulence (297).  These studies revealed 4 critical genetic determinants of S300 
neurovirulence, with 3 in the nonstructural genes and 1 in the structural genes.  These 
determinants include the aforementioned nsP1 T538I (Thr is virulent), an 18 amino acid 
deletion within the C-terminus of nsP3 (deletion is virulent), nsP3 Opal537Cys (Cys is 
virulent), and E2 Leu243Ser (Ser is virulent).  Initially, the mutation of these single 
attenuating mutations suggested their role as determinants.  Furthermore, introduction of all 4 
determinants into the avirulent G100 background was able to rescue nearly full virulence of 
S300.  Similar to G100, when the 4 attenuating are introduced into the S300 backbone, this 
virus can establish infection within the CNS equivalent to S300, but is more efficiently 
controlled at late times post-infection (297).   
 
1.5 The complexity of the immune response to invading pathogens within the CNS  
 
The CNS, once coined an “immune privileged” site due to its tolerance of allogeneic 
cells, is now known to be capable of mounting a potent, yet tightly controlled response to 
microbial attack.  Neurons are non-renewable cells, whose loss or damage results in 
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paralysis, seizures, and cognitive impairment. Therefore, in order to protect these critical 
cells, the immune system employs mechanisms to orchestrate viral clearance through a 
highly regulated and noncytolytic process (reviewed in (110)).   
Multiple mechanisms are in place as a means to protect neurons within the CNS from 
invasion by pathogens, and neuronal death and damage.  Ironically, many of these 
mechanisms can be advantageous for the pathogen.  Furthermore, the interconnectedness of 
the neurons themselves can facilitate spread of pathogens.  Unlike other organs, the CNS is 
maintained in a relatively quiescent state in large part due to blood-brain barrier (BBB), 
which is composed of endothelial tight junctions and maintained by astrocytes.   Although 
activated T cells are permitted to cross the BBB, they either die or exit when antigen is not 
detected (126, 135).   
Once a virus invades the CNS, PRRs detect the virus, and initiate the antiviral 
response.  Early during infection, resident glial cells become activated and are the major 
producers of chemokines, pro-inflammatory cytokines, and matrix metalloproteinases 
(MMPs) (17).  Specifically, IL-6, MMP-9, and possibly TNF-α have been shown to disrupt 
the blood-brain barrier (137, 327).  Chemokines and cytokines increase the expression of 
MHC on microglia and adhesion molecules on cerebral capillary endothelial cells, both of 
which facilitate immune cell infiltration into the CNS (173, 250).  The chemokines, CXCL10 
and CCR5, recruit virus-specific T cells to the brain, and are important for the immune 
response to mouse-hepatitis virus and WNV (99, 155, 174).  Although chemokines have been 
found to be protective during infection with neurotropic viruses, prolonged expression of 
chemokines can lead to demyelination and damage in the CNS (15, 174). 
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Viral clearance from the CNS 
The paradigm for viral infections of the CNS is that the innate immune system and 
type I IFN control viral replication early during infection (37, 85, 260), however the adaptive 
immune response and IFN-γ and in some case perforin, are essential for clearance of the 
virus (17, 34, 108).  Owing to the lack of MHC class II expression on neurons, astrocytes, 
and oligodendrocytes, CD4+ T cells likely do not possess direct antiviral activity (108).  
However, microglia, along with infiltrating monocytes and DCs express and can up regulate 
MHC class II expression, and thus cross-presentation may contribute to T cell mediated 
clearance (reviewed in (270)).  
Clearance of virus from the CNS requires first clearance of cell-free virus, next 
abrogation of intracellular viral replication, and finally the elimination of viral nucleic acid 
(reviewed in (110).  The critical protective role of IFN-γ has been extensively dissected in a 
SINV mouse model (strains related to TR339), and T cell production of IFN-γ is critical for 
clearance during other neurotropic viruses such as Borna disease virus, Theiler’s murine 
encephalomyelitis virus, MHV, and measles (118) (238, 239, 253).  The molecular 
mechanism of IFN-γ-mediated clearance is not fully understood; however the efficacy of 
IFN-γ most likely lies in its unique ability to inhibit viral replication, while also maintaining 
the viability of infected neurons.       
 
Clearance of alphaviruses from the CNS 
TR339, the prototypic SINV, is avirulent in adult mice, and as such peak titers are 
reached in the CNS by day 2 pi, with clearance of infectious virus occurring by day 7 pi 
(209).  Therefore most studies to evaluate the role of adaptive immunity during TR339 
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infection were performed in RAG-1-/- or SCID mice which lack functional B and T cells, and 
support lifelong persistent infection.  These studies have demonstrated a protective and 
synergistic role for antibody and IFN-γ (34), have been extensively discussed in literature 
reviews, and have served as a model of IFN-γ-mediated noncytolytic clearance from neurons.   
Persistent infection of adult scid/CB17 mice with TR339 was cleared by treatment 
with virus-specific monoclonal antibodies to the E2 glycoprotein, but not by transfer of 
sensitized T cells (184).  While µMT mice, which lack functional B cells, had a clearance 
defect in the brain, virus in the spinal cord was cleared with similar kinetics to wild type mice 
(21).   Therefore, an antibody-independent mechanism could drive clearance in the spinal 
cord.  Binder et al. showed that either CD8+ or CD4+ T cells could mediate clearance from 
the spinal cord of persistently infected RAG-1-/- mice (21).  The T cell effector function that 
drove clearance was found to be IFN-γ.  When SCID mice were infected with strain TE 
(TR399 expressing His at E2 position 55) expressing IFN-γ from a second subgenomic 
promoter, virus was cleared from the spinal cord, equivalently to µMT mice infected with 
TR339 expressing an irrelevant control transgene (21).  The fact that neither IFN-γ R-/- nor 
IFN-γ-/- (GKO) displayed clearance defects was overshadowed by the phenotype observed in 
µMT/GKO double-knockout mice.  The double deficiency resulted in a defect in clearing 
virus from the brain stem and spinal cord, locations from which virus was cleared in µMT 
mice.  These studies suggested that antibody and IFN-γ may synergistically clear virus from 
the specific locations within the CNS (21).    
Not only are the murine diseases caused by NSV and TR339 dramatically different, 
but some of the interactions with host pathways are also distinct.  For example, mice 
deficient in IFN-γ, CD4+ T cells, β2-microglobulin (which depletes MHC class I), but not 
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mice deficient in CD8+ T cells  showed increased survival and reduced hippocampal damage 
upon infection with NSV (152, 255, 336).  The discrepancy between NSV phenotypes within 
CD8+ T cell deficient mice and β2-microglobulin deficient mice has yet to be fully 
understood.  
The in vivo neuronal cell death and mortality that occurs with NSV infection can be 
diminished by blocking the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA) receptor.  Hyperstimulation of the AMPA receptor is known to result in excitotoxic 
death within neurons (49).  Interestingly, blockade of AMPA receptor resulted in delayed 
viral clearance, thereby suggesting that NSV-induced neuronal death is not due to viral 
replication, but rather the host immune response.  NSV infection correlates with an increase 
in TNF-α expression, and TNF-α was shown to down regulate the glutamate transporter 
(GLT-1) on astrocytes, thereby increasing excitotoxic neuronal death (41).  Consequently, 
TNF-α deficient mice exhibit a dramatic reduction in neuronal cell death and reduced 
mortality.   
In addition to the marked differences in disease between SINV strains that are 
avirulent in adult mice (TR339 and G100) versus those that are neurovirulent in adult mice 
(NSV and AR86), there are significant differences in the characteristics of NSV and AR86-
induced neurologic disease.  First, S300 replication within the CNS is not cleared, and peak 
titers coincide with death between days 5-7 dpi.  Moreover, all mouse strains infected to date 
succumb to S300 i.c. infection, with one possible exception being IFN-γ cytokine-/- mice 
(unpublished results).  In contrast, NSV replication in the CNS peaks at 3 dpi, is controlled 
by 5 dpi, and is cleared from the brain and spinal cord by days 10 and 7 pi, respectively 
(152).  Thus, mice die from NSV infection after peak titers are reached, suggesting that 
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immune-pathology may be responsible for disease exacerbation and death.  This hypothesis 
is confirmed by the studies discussed earlier in this chapter that found that CD4+ T cells and 
IFN-γ deficient mice are protected from disease.   
A recent study investigated the role of TLRs during NSV viral infection.  
Specifically, Esen et al. infected Unc93b13d/3d mice, which functionally ablates TLR3, TLR7, 
and TLR9 signaling.  These mice fail to transfer TLRs from the ER to the endosome (151, 
299).  While Unc93b13d/3d mice were more susceptible to NSV infection, neither MyD88-/- 
nor TLR3-/- mice were more susceptible, suggesting that TLRs do not regulate the 
pathogenesis to NSV infection (72).  However, a TLR-independent effect of mutating 
Unc93b13d/3d may have a protective role in NSV neurovirulence.   
 
1.6 The type I IFN system 
 
Discovery of interferon 
In 1957, Alick Isaacs and Jean Lindenmann performed the landmark experiments that 
are recognized today as the first demonstration of IFN activity.  The scientists treated chicken 
chorioallantoic membranes with heat-inactivated influenza to elicit production of IFN.  This 
IFN was able to inhibit live influenza virus growth on fresh membranes (136).  Three years 
prior, in 1954, Yasuichi Nagano and Yasuhiko Kojima of Japan, had demonstrated in vivo 
the phenomenon of interferon inhibiting viral growth, and had named this activity, “virus 
inhibitory factor” (222).  However, Nagano and Kojima’s work has received little credit in 
the discovery of IFN, possibly due to the complication of using an in vivo model.  
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Undoubtedly the discovery of IFN, the first identified cytokine, has spawned an entire branch 
of scientific research.  
The IFN family consists of structurally related cytokines that possess antiviral activity 
and are found exclusively in vertebrates (reviewed in (301)).  At first, IFN was recognized 
for its antiviral properties, however further research demonstrated the additional 
immunomodulatory and antitumor effects of IFN (242).  IFNs are classified into types, based 
upon the specific receptor through which they signal.  Type I IFNs include IFN-α (that 
includes at least 14 subtypes), -β, -ω, and –ε, however most studies have focused on IFN-α/β 
(175).  All type I IFNs signal through the IFN-α/β receptor, IFNAR1 and IFNAR2.  Type I 
IFNs are induced in virally infected cells or uninfected cells with macrophages and DCs 
being the major type I IFN producers in vivo.  Type I IFN contributes to DC maturation, NK 
cell activation, antibody production, and T cells responses, thereby acting as a bridge to the 
adaptive immune response (129).   
 
Pattern recognition receptors  
Since the discovery of the Toll-like receptors (TLRs) in the mid-1990s, the specificity 
and complexity of the innate immune system has begun to be appreciated (6).  The term 
pattern-recognition receptor (PRR) refers to a molecule that recognizes specific motifs, or 
pattern-associated molecular patterns (PAMPs), that are foreign, and not normally present in 
the host (7, 213).  PRRs include TLRs, RLRs, and Nod-like receptors (NLRs).  NLRs will 
not be discussed here, because there has been little evidence thus far of NLR regulation of 
alphavirus pathogenesis.   
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Activation of PRRs leads to the production of type I IFN and inflammatory cytokines, 
and the transcriptional induction of hundreds of ISGs.  The PRR signaling cascade is initiated 
upon recognition of specific PAMPs, followed by the phosphorylation and translocation of 
latent cytoplasmic transcription factors, including IRF3, IRF7, NF-κB, and ATF2/cJun.  
Together, these 4 transcription factors comprise the enhanceosome, and bind the IFN-β 
promoter region to optimally induce its transcription (74, 132, 244). 
 
TLR recognition of RNA virus PAMPs 
All TLRs, except TLR3, signal through the MyD88 adaptor protein.  TLR2 and TLR4 
require the Mal/TIRAP adaptor in order to recruit MyD88 to the cell surface (52).  TLR3 
recruits the adaptor protein, TIR-domain-containing adapter-inducing interferon-β (TRIF).  
TLR4 can recruit either MyD88 or TRIF, with the latter requiring the initial recruitment of 
the adaptor protein TRIF-related adaptor molecule (TRAM).  TLR signaling cascades result 
in the activation of NF-κB, mitogen-activated protein kinase (MAPK), and interferon 
regulatory factors (IRFs) 1, 3, 5, and 7 (130).  TLR3 and TLR7 (analogous to human TLR8) 
localize to the endosome, often the site of viral uncoating, where they are poised to recognize 
viral RNA.  TLR3 recognizes double-stranded RNA (dsRNA) while TLR7 recognizes 
ssRNA (reviewed in (28)).  TLR2 and TLR4 localize to the cell surface, where they 
recognize viral envelope proteins.   
 
RLR recognition of RNA virus PAMPs   
The RLRs, RIG-I, MDA5, and LGP2, are cytoplasmic and recognize viral RNA 
motifs.  All 3 RLRs contain a DexD/H box C-terminal RNA helicase domain, while RIG-I 
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and MDA5 also contain an N-terminal caspase activation and recruitment (CARD) domain, 
and RIG-I and LGP2 possess a C-terminal repressor domain.   RIG-I recognizes free 5’ 
triphosphates on viral RNA often in combination with polyUridine-rich motifs, and RIG-I 
has been shown to recognize hepatitis C virus, Sendai virus, influenza virus, vesicular 
stomatitis virus, rabies virus, and JEV (97, 132, 145, 244).  Efficient activation of RIG-I may 
require not only RNA-motif recognition, but also Lys-63-linked ubiquitination by tripartite 
motif 25 (TRIM 25) (89).  MDA5 recognizes long double-stranded RNA, and has been 
shown to recognize picornoviruses and noroviruses (144, 145, 208).  Conflicting evidence 
exists as to the role of LGP2, with original reports suggesting it was a negative regulator of 
RLR signaling, and recent reports suggesting the opposite (269, 320).  One possible 
mechanism of LGP2 regulation is that LGP2 acts upstream of RIG-I and MDA5 by 
unwinding or removing nucleoproteins from viral RNA (89).  
Once activated, both RIG-I and MDA5 interact with IPS-1(also known as MAVS, 
Cardif, or Visa) via CARD-CARD interactions (148, 212, 281, 342).  IPS-1 localizes to 
mitochondrial associated membranes (MAMs) and peroxisomes (131).  The activated RIG-I-
IPS-1 or MDA5-IPS1 complex requires an additional interaction with tumor necrosis factor 
(TNF) receptor-associated factor (TRAF)3 to mediate IRF3/IRF7 activation and downstream 
type I IFN induction (264).  IRF3 and IRF7 can either form homodimers or heterodimers, 
whereby IRF3 homodimers strongly induces IFN-β over IFN-α, and IRF7 activates both type 
I IFNs (268).  NF-κB activation requires interaction between IPS-1 and TRAF2 and TRAF6 
(342).   
 RNAseL is an endonuclease that can cleave viral or host RNA, thereby providing a 
ligand for RIG-I and MDA5 (201).  Another example of a PRR is the IFN-inducible, protein 
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kinase R (PKR) that recognizes dsRNA.  PKR is involved in the host response to stress, and 
has recently been shown to enhance type I IFN by a distinct mechanism (13, 42, 96).   PKR 
stabilizes and preserves IFN-α/β mRNA, thus allowing for ongoing translation (278).  In 
addition, PKR phosphorylates eIF-2α, which inhibits host and certain viral protein synthesis, 
and activates the cellular stress response (340, 341).  Interestingly, translation of SINV 26S 
RNA, but not genomic RNA persists, despite the fact that nearly all of eIF2α is activated by 
phosphorylation during SINV infection (321).  The translation of 26 RNA in the presence of 
phosphorylated eIF2α was dependent upon a hairpin loop RNA (DLP) structure downstream 
of the AUG codon.  Ventoso et al. hypothesize that the DLP may allow the ribosome to 
pause at the first AUG and deliver the Met-tRNAi to the ribosome (321).  Thus SINV is able 
to overcome translation inhibition despite abundant eIF2α phosphorylation.  Even more 
surprisingly, shut-off of host translation during SINV infection is IFN-dependent but 
independent of PKR (262).    PKR deficient mice are not more susceptible to SINV infection 
(262).  However, PKR-/- DCs support greater levels of SINV infection (262, 263).   
 
PRRs that mediate type I IFN induction in response to alphavirus infection 
Despite the abundance of studies demonstrating the paramount role for IFN-α/β in 
vivo, the mechanism by which alphaviruses stimulate IFN-α/β induction is not well 
understood.  A limited number of studies have examined the PRRs required for IFN-α/β upon 
alphavirus infection.  Moreover, type I IFN induction and PRR expression is cell type 
specific, with TLR expression highest on DCs and macrophages, and RLR expression 
ubiquitous.  To further complicate analysis, IFN induction by monocytes often does not 
require active viral replication, while IFN induction by fibroblasts via RLRs often does 
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require active viral replication.  Alphaviruses possess dramatically different potencies of 
antagonism of and sensitivity to type I IFN, and therefore careful evaluation and comparison 
among virus strains is critical.     
In myeloid DCs (mDCs) infected with SFV, IRF3 but not MyD88 was required for 
IFN-α/β production, and this effect did not require replication (127).  However, viral 
replication was required for IRF3 activation in fibroblasts (14).  Primary DCs and 
macrophages infected with SINV showed a minor contribution of MDA5 to IFN-α/β 
production, but no role for PKR (97, 262).  Induction of type I IFN in MEFs infected with a 
noncytopathic SINV that does not shut-off host macromolecular synthesis required MDA5 
and PKR, but not RIG-I.  However, wild type SINV (TR339) did not induce detectable type I 
IFN in MEFs (35). In human foreskin fibroblasts, CHIKV induction of IFN-β and ISGs 
mRNAs is IRF3 and IPS-1-dependent, however CHIKV was so efficient at blocking cellular 
protein synthesis that no corresponding IFN-β protein could be detected, even at high MOIs 
(337).    Finally, in MEFs, Schilte et al. demonstrate that RIG-I, but not MDA5 is required 
for IFN-β transcription during CHIKV infection (273).   
The aforementioned studies illustrate the complexity of alphavirus induction of type I 
IFN, which depends upon cell type, virus strain, and may or may not require replication.  
Therefore future studies should assess the PRRs required for type I IFN induction within 
multiple cell types upon infection with multiple alphaviruses.   
 
Type I IFN signaling/amplification 
Once a virally infected cell senses a PAMP, PRR signaling cascades become 
activated, and early during this process, IFN-β is secreted.  Secreted IFN-β binds to the 
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heterodimeric IFNAR1 and IFNAR2 receptor subunits on either infected or uninfected 
surrounding cells.  The IFNAR1 and IFNAR2 receptors are constitutively associated at their 
cytoplasmic domains with the Janus kinases (Jaks), Tyk2 and Jak1, respectively (339).  Once 
IFNAR recognizes its ligand, Tyk2 and Jak1 undergo trans or auto-phosphorylation, to allow 
docking sites for STAT1 and STAT2 proteins via SH2 domain interactions (51, 93, 220, 
344).  STAT1 and STAT2, themselves become phosphorylated by Jak1 and Tyk2, and 
subsequently heterodimerize and disassociate from the receptor complex.  The STAT 
heterodimer associates with IRF9 in the cytoplasm, and this complex is named the IFN-
stimulated gene factor 3 (ISGF3) complex (88, 185).  The ISGF3 complex translocates to the 
nucleus, where it binds to promoters with interferon-stimulated response elements (ISREs) 
elements and activates the transcription of hundreds of genes (245).   
 
Evidence for the contribution of type I IFN to the adaptive immune response 
Type I IFN is known to inhibit viral replication at very early stages and also to 
contribute to the adaptive immune response by priming B and T cells.  Specifically type I 
IFN modulates B cell activation, induces DC maturation, and stimulates antigen presentation 
(179, 311).  Eloquent mechanistic studies have shown that type I IFN acts directly on T cells, 
B cells, and DCs.  Type I IFN signaling in T cells leads to prolonged survival and 
proliferation, the latter occurring only T cells are exposed to type I IFN very shortly before 
infection or to activated T cells   (76, 205).   However, type I IFN has an antiproliferative 
effect on resting T cells.  Analysis of the expression profile of resting versus activated T cells 
showed that activated T cells displayed reduced expression of STAT1 and other ISGs 
compared to resting T cells (205).  Because STAT1 is required for the anti-proliferative 
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effect of type I IFN, the unique ability of activated T cells to maintain low STAT1 expression 
may explain part of the proliferative effect.   
Interestingly, a recent study showed that B cells contributed to protection against 
VSV, and that this effect was independent of humoral or cell-mediated adaptive immunity.  
Instead, B cells were the source of lymphotoxin (LT) α1β2, which directed subcapsular sinus 
macrophage differentiation, a prerequisite for VSV permissiveness and subsequent type I 
IFN production (218).   
 
Type II IFN   
 IFN-γ was discovered in 1965, as a protein secreted by activated lymphocytes and 
possessing antiviral activity (241).  IFN-γ is the only type II IFN, and unlike type I IFN, IFN-
γ is not secreted by virally infected cells (11).  IFN-γ is produced by NK cells, CD4+ and 
CD8+ T cells, macrophages, and other myeloid cells (87), and is required for the activation of 
macrophages, CD4+ T cells and CD8+ T cells (134).  IFN-γ also contributes to the antibody 
response by affecting IgG heavy chain switching (79).  The IFN-γ signaling cascade mirrors 
type I IFN signaling, with a few exceptions.  IFN-γ binds and signals through the cell surface 
receptors, IFNGR1 and IFNGR2.  IFNGR1 and IFNGR2 bind tightly to Jak1 and Jak2, 
respectively (11).  The major IFN-γ signaling pathway proceeds with the 
autophosphorylation of Jak1 and Jak2, which creates a binding site for phosphorylated 
STAT1.  Next, STAT1 homodimers (also known as Gamma-Activated Factor) translocate to 
the nucleus, bind GAS promoter elements, and recruit transcriptional co-activators that 
induce the transcription of primary responsive genes including the transcription factor IRF1.  
Unlike ISRE promoter elements, which exclusively bind ISGF3, GAS promoter elements are 
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recognized by STAT1, 3, 4, 5, or 6 homodimers, and multiple combinations of heterodimers 
(245).  Subsequently IRF1 binds to ISREs to induce a multitude of ISGs.  Since prolonged 
IFN-γ expression is harmful, IFN-γ induces the expression of suppressor of cytokine 
signaling (SOCS) genes that serve to dampen IFN-γ signaling (245).   
 
Type III IFN 
Type III IFNs include IFN-λs, also referred to as IL-28/29 (285, 165).  Type III IFNs 
bind to the IL-28Rα/IL-10Rβ heterodimeric receptor, and also signal through the ISGF3 
complex (9).  This family of antiviral cytokines is not as well-studied as type I or type II IFN, 
and will not be discussed further in this dissertation.  
 
Type I and type II IFN crosstalk 
The type I and II IFN induction pathways do not always follow the canonical 
pathways as described above.  For example, type I IFNs can promote STAT1 homodimer 
formation and thereby stimulate expression of GAS-containing genes, and conversely IFN-γ 
can induce a modified ISGF3 complex that can bind ISREs (187, 217) 
Recent studies have demonstrated a critical role for the constitutive, albeit low level 
expression of IFN-α/β.   Specifically, constitutive IFN-α/β is required for robust responses to 
IFN-γ and IL-6 (215, 300).  However, IFN-α/β is maintained at basally low levels by the 
negative regulation by IRF-2 (304).   
The mechanism by which IFN-γ exerts antiviral activity is not fully understood. 
However part of the antiviral effect of IFN-γ may be a result of up regulation of Mx, 
RNaseL, 2’5’-oligoadenylate synthetase (2’-5’ OAS), PKR, and NOS.  Among these effector 
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molecules, Mx and RNaseL do not possess in vivo anti-SINV capacity (263), 2’-5’ OAS 
inhibits TR339 replication in vitro (27), PKR does not affect SINV replication in vivo but has 
a minor role in vitro, and inhibition of NOS increases NSV mortality in vivo (189, 262, 314).  
NO can be produced in the CNS by any of the 3 isoforms of nitric oxide synthase (NOS): by 
neuronal NOS (nNOS or type I NOS), by glial or macrophage inducible NOS (iNOS or type 
II NOS), and by neuronal and endothelial type III NOS (12, 224).  IFN-γ inhibits replication 
of Vesicular Stomatitis virus (VSV), JEV, polio virus, HSV-1, influenza, and AR339 in a 
neuroblastoma cell line, an effect that was mediated by nNOS for all viruses except AR339 
and influenza (19, 164, 189).   Inhibition of NOS increased mortality in vivo following NSV, 
JEV, and VSV infection (121, 123, 189, 314).   
While the protective role of IFN-γ has been extensively discussed, there is also 
increasing, albeit controversial data suggesting that IFN-γ is involved in autoimmune 
disorders such as allergic encephalomyelitis, and insulin-dependent diabetes mellitus (77, 
322).  Moreover, prolonged exposure of neurons to IFN-γ results in dendritic retraction 
(204).   
 
1.7 Alphavirus interactions with the host innate immune system 
 
Alphavirus evasion of innate immunity  
The ability of alphaviruses to shut off host RNA and protein synthesis in vitro has 
been well established as a potent mechanism that alphaviruses employ to antagonize the host 
immune response.  Importantly, the shut off phenomenon was also recently shown to occur 
within SINV-infected neurons in vivo (310).  Old World alphaviruses employ nsP2 to shut-
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off host synthesis, while New World viruses carry out this function with capsid (3, 26, 85).   
The precise mechanism of alphavirus shut off of host translation remains unclear.  
Mechanistic understanding of host shut off has been complicated by the fact that alphavirus 
infection results in PKR-dependent phosphorylation of nearly all of the available eIF2α 
(321).  eIF2 contains three subunits (α, β, and γ), that are required for the delivery of Met-
tRNAi to the ribosome, and thereby initiate protein synthesis at the corresponding AUG 
codon.  Surprisingly, shut off of host translation occurred equivalently after SINV infection 
of wild-type or PKR-/- NIH 3T3 cells, thereby suggesting that PKR does not mediate 
inhibition of host macromolecular synthesis (101).   
Recent evidence suggests that Old World viruses block cellular transcription by an 
nsP2-dependent degradation of Rpb1, a catalytic component of RNA polymerase II (5).  New 
World alphaviruses encode a nuclear localization signal within capsid protein, which blocks 
nuclear pores and nuclear import of cellular proteins with nuclear localization signals (10).  
This mechanism is thought to result in the downregulation of cellular transcription.   
Until recently, global, nonspecific shut off was proposed to be the sole mechanism of 
alphavirus antagonism of the type I IFN response.  Simmons et al. described a specific 
abrogation of Jak/STAT signaling upon infection with VEEV or SINV that occurred prior to 
shut off, and further demonstrated that in the case of SINV, this activity was dependent on 
the nsP1 position 538 Thr virulence determinant (289).       
 
ISGs 
Much emphasis has been placed on understanding the mechanism by which specific 
ISGs exert antiviral effector activity against alphaviruses.  To this end, multiple studies have 
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identified host molecules with anti-SINV properties both in vitro and in vivo.  Of note, the 
studies described below were performed with TR339 or a derivative thereof, using the 
neonatal model of a SIRS-like infection.  Therefore the role of these molecules in protection 
from AR86 or NSV may or may not be similar.  The SINV genome is highly sensitive to the 
addition of nucleotides, as marked by its small genome.  Therefore, nearly all double-
subgenomic viruses are attenuated in vivo, and difficulty arises in the interpretation of 
pathogenesis studies performed with such viruses.  However, these studies have begun to 
describe the complex interaction between virus and host, with a focus on the type I IFN 
response.   
Zhang et al. expressed several candidate ISGs off of a double-subgenomic SINV, and 
demonstrated that zinc finger antiviral protein (ZAP), and viperin expressing viruses were 
attenuated in vivo (350).  In vitro siRNA and overexpression experiments suggested that 
ISG20 and ZAP were strong inhibitors of SINV replication, while viperin, p56 (ISG56), and 
ISG15 moderately inhibited SINV replication (350).  In addition, ZAP was shown to inhibit 
in vitro replication of other alphaviruses, including RRV, SFV, and VEEV, along with other 
viruses (20). 
 
ISG15 
ISG15 is noted for being rapidly induced upon viral induction and type I IFN.  Owing 
to its ubiquitin-like homology, ISG15 becomes conjugated to greater than 300 cellular and 
viral proteins (95, 200, 302, 351).  Although these ISGylated proteins do not cluster by 
functionality or localization, they were found to be newly synthesized proteins (70).  ISG15-/- 
mice are not only more susceptible to TR339, but the expression of ISG15 from a second 
34 
 
subgenomic promoter confers protection in the highly susceptible adult Ifnar-/- mice (181).  
In this case, utilizing a double-subgenomic virus for a gain-of-function readout does not have 
the same caveats as mentioned above.   
ISG15 possesses antiviral activity against a diverse range of viruses, and this activity 
is sometimes, but not always linked to the conjugation of ISG15 to proteins (182).  In the 
case of HIV-1, Ebola, and VSV, ISG15 blocks budding from the infected cell by 
antagonizing the pro-viral ubiquitination modification of viral proteins.  Further confirmation 
of ISG15’s antiviral role is that viruses have evolved strategies to directly antagonize ISG15.   
 
Viperin 
Viperin is a highly conserved protein that localizes to the ER, lipid droplets, and in 
the case of human cytomegalovirus (HCMV) infection, to the mitochondria (reviewed in 
(280)).  Despite being identified as having antiviral activity towards numerous viruses, the 
mechanism by which viperin exerts antiviral activity is largely unknown. Viperin is induced 
by IFN-γ in macrophages, and by type I IFN in most cell types.  Viperin is also induced an 
IRF-3 and IRF7-dependent manner by dsRNA, poly I:C, and SINV, along with other viruses.  
Upon infection with vesicular stomatitis (VSV), viperin is induced early via a peroxisome-
localized IPS-1 pathway, and late via a mitochondrial-localized IPS-1 pathway (67).      
 
ZAP 
The ZAP protein inhibits the replication of multiple members of the alphavirus genus, 
along with members of the Filoviridae family.  As its name suggests, ZAP contains 4 CCCH-
type zing-finger motifs within its N-terminus that mediate binding to viral RNA in the 
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cytoplasm (20, 91, 114).  The mechanism of anti-alphavirus activity by ZAP has not been 
confirmed, however ZAP was shown to block an early stage of SINV replication, prior to 
viral polyprotein synthesis (20).   
The mechanism by which ZAP exerts its antiviral activity during Moloney murine 
leukemia virus involves the binding of ZAP to viral RNA and subsequent shuttling of the 
RNA to the exosome.  Cytoplasmic exosomes mediate degradation of certain unused or 
erroneous RNAs, however the details of exosomal RNA degradation via ZAP is poorly 
understood.   
Alternative splicing results in production of two ZAP isoforms, the longer of which 
possesses greater anti-alphavirus activity (149).  Interestingly, ZAP was found to synergize 
with multiple ISGs during SINV infection, including some members of the RNA sensing and 
induction pathways (IRF7, MYD88, MDA5, RIG-I, and IRF2) (143).  In addition, the short 
isoform of ZAP (ZAPS) interacts with RIG-I to increase the type I IFN response, an effect 
which may have implications during SINV infection (120).   
ZAP commonly recognizes an AU-rich element (ARE) within RNA, however this 
element is not recognized within SINV.  However, understanding the ARE-dependent 
mechanism of ZAP may provide a basis for understanding the mechanism of ZAP activity 
during SINV infection.  In the context of ARE-expressing RNA, the first and rate-limiting 
step is the removal of the poly(A) tail by cellular deadenylases, followed by 3’-5’ 
degradation of the remaining RNA (48, 219).  Interestingly, SINV represses deadenylation 
by binding of specific viral RNA motifs to the host HuR protein (293).  The HuR protein 
stabilizes the viral genomic RNA, and this mechanism occurs in both mosquito and 
mammalian cells.  Interestingly, while mosquito HuR is cytoplasmic, mammalian HuR is 
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nuclear.  Remarkably, during SINV infection, HuR is translocated from the nucleus to the 
cytoplasm (293).   
 
Potential anti-SINV role for IFIT family members 
An initial study suggested that ISG54 and ISG56 (hereafter referred to as interferon-
induced protein with tetratricopeptide repeats, IFIT2 and IFIT1, respectively) did not play 
major roles in modulation of SINV in vitro or in vivo (349).  However, because studies from 
our lab suggest that attenuated RRV (Cruz, C, unpublished results), and possibly SINV 
mutants activate the type I IFN response by exposing free 5’ RNA triphosphates, these 
molecules may have relevance during the attenuated alphavirus infection.  Furthermore, 
initial studies in our laboratory suggest that IFIT1 and IFIT2 may inhibit SINV replication in 
IFN-β primed cells.       
IFITs are induced by type I IFN, and reach extremely high expression levels.  By 
using a proteomics approach, IFIT1 was shown to bind uncapped RNA, and IFIT1, IFIT2 
and IFIT3 all form a complex (243).  Mice lacking Ifit1 were more susceptible and supported 
higher levels of infection when infected with viruses that express uncapped RNA, but not 
with those that do not (243).  Interestingly, a WNV mutant which lacks 2’O-methylase 
activity, a modification that occurs on cellular and viral RNA CAP structures, was more 
sensitive than wt WNV to the antiviral effects of IFITs (57).   
 
Autophagy 
Autophagy, and specifically ‘immunological autophagy’ has gained significant 
attention in terms of its role in innate immunity.  This evolutionarily conserved pathway is 
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protective during SINV infection of mice.  Overexpression of Beclin 1 (the mammalian Atg6 
ortholog) in neurons protects neonatal mice against lethal SINV infection (188).  A recent 
study demonstrated that Atg5 deficient mice are also more susceptible to lethal SINV 
infection, which is characterized by increased neuronal death (231).  Furthermore, the 
cellular autophagy protein, p62, binds to and targets the SINV capsid protein to the 
autophagosome (231).  Autophagy involves the formation of intracellular double membrane-
bound autophagosomes, which, in general mediate digestion of cellular material.  
Interestingly, autophagy pathways interact with PRRs, and autophagy has been shown to be a 
negative regulator of RLR signaling (reviewed in (265)).  Future studies should be 
undertaken to determine the potential cross-talk between RLR pathways and autophagy 
during SINV infection.   
 
1.8 Dissertation objectives 
 
The introduction to this dissertation provides an overview of what is currently known 
regarding host-pathogen dynamics during alphavirus infection, with a particular emphasis on 
SINV.  As a biosafety level-2 pathogen that causes neurologic disease is mice, but not 
humans, SINV strain AR86 is an ideal tool to rapidly increase our understanding and develop 
therapeutic targets against the pathogenic alphaviruses.  One major gap in our understanding 
of SINV biology is the mechanism by which the host recognizes viral PAMPs, and which 
host genes are required for eliciting recovery and preservation of neurons.  Secondly, 
alphavirologists do not fully understand which aspects of adaptive immunity are directly 
stimulated by type I IFN during alphavirus-induced neurologic disease.   Furthermore, if 
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IFN-γ is indeed pathogenic during infection with neurovirulent strains of SINV, then further 
studies are necessary to understand this mechanism.   
The first goal of this dissertation was to determine which host sensing pathway was 
required for the attenuation of nsP1 T538I in vivo.  To address this aim, mice deficient in 
each of the adaptor molecules essential for PRR signaling were infected with S300 or nsP1 
T538I and intensively analyzed for disease correlates.  These studies demonstrated that the 
RLR-dependent IPS-1 pathway is essential for the attenuation of nsp1 T538I, while the 
TLR3-dependent TRIF pathway is modestly protective against SINV in general.   
 A second major aim of these studies was to understand the components of adaptive 
immunity that mediated the attenuation of nsP1 T538I.  These studies demonstrated additive 
contributions of T and B cells to mediating protection and control of the mutant nsP1 T538I 
virus.  Furthermore, expression of the IFN-α/β receptor on lymphocytes was dispensable for 
mediating control of nsP1 T538I replication.  While the IFN-γ receptor did not regulate 
SINV pathogenesis, mice lacking IFN-γ cytokine showed ameliorated disease with both S300 
and nsP1 T538I.   
 These studies were designed to begin to understand how a mutation within the nsPs is 
detected, eliminated, and cleared in vivo.  The following aims were addressed:   
Aim 1:  To determine the roles of the Toll-like receptor (TLR) and the RIG-I-like 
receptor (RLR) host sensing pathways in promoting viral control and protection during 
AR86 infection. 
Aim 2:  To determine the role of adaptive immunity in promoting viral control and 
recovery during AR86 infection.
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CHAPTER TWO: 
 
AN ATTENUATING MUTATION IN A NEUROVIRULENT SINDBIS VIRUS 
STRAIN INTERACTS WITH THE IPS-1 SIGNALING PATHWAY IN VIVO 
 
 
 
2.1 Introduction 
 
Encephalitic viruses represent an important public health threat due to their high rate 
of mortality and worldwide distribution.    Sindbis virus (SINV), the prototypic alphavirus, 
provides an excellent model of viral-induced encephalomyelitis, and serves as a model of the 
complex process of viral clearance from neurons (reviewed in (110)).  Survival of mice 
infected with SINV is dependent on a number of factors including viral genetics, host age, 
and interactions with the host innate and adaptive immune pathways (68, 112, 122, 142, 160, 
170, 236, 260, 315, 316). 
Among multiple SINV virus strains in the literature, wild-type AR86 (hereafter S300) 
and neuro-adapted NSV, are unique for their ability to cause lethal neurologic disease in 
adult mice (291, 332).  Previous studies with S300 identified four viral genetic determinants 
of adult neurovirulence in outbred CD-1 mice, three of which were in the nonstructural 
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proteins (297).  One of these determinants, a threonine (Thr) codon at nsP1 position 538, is 
essential for S300 neurovirulence, where an attenuating isoleucine (Ile, consensus among 
non-neurovirulent SINV viruses) at this position accelerates polyprotein processing and 
expression from the 26S RNA promoter (123).  S300 expressing this Ile (referred to as 
nsP1T538I hereafter), has no defect in its ability to establish infection within the CNS, even 
exhibiting increased early replication as compared to S300.  However, in CD-1 mice, nsP1 
T538I viral RNA within the brain was nearly undetectable at late times pi (122).  
Type I interferon (interferon alpha/beta [IFN-α/β]) is critical for host survival upon 
infections with alphaviruses (260, 338).  Indeed, SINV is highly sensitive to the antiviral 
effects of IFN-α/β (345), and in vitro data suggest that SINV antagonizes IFN-α/β induction 
via global shutoff of host macromolecular synthesis (35, 85).  However, the nsP1 T538I virus 
shuts off host macromolecular synthesis equivalently to S300, but nsP1 T538I induces 
significantly more type I IFN both in vitro and vivo, and nsP1 T538I fails to antagonize early 
type I or II IFN-dependent signaling at or before the level of STAT phosphorylation (56, 
289), suggesting that this determinant affects neurovirulence via specific interactions with the 
type I IFN pathway. 
The type I IFN response to RNA viruses is initiated by the ligation of ‘foreign’ 
pattern associated molecular patterns (PAMPs) to specific Pattern Recognition Receptors 
(PRRs), which include the Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs) (139, 
317).  The TLR family is comprised of 12 known murine transmembrane receptors (human 
TLR8 functions analogously to murine TLR7), including four that are known to recognize 
RNA virus PAMPs (TLR-3, -4, -7, and -8) (6, 28, 52, 207, 318, 346).  TLRs are type I 
transmembrane proteins that contain extracellular leucine-rich repeats (LRRs), required to 
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detect PAMPs, and a cytoplasmic Toll/interleukin-1 receptor (TIR) domain, required for 
activation of downstream signaling pathways.  TLR3 and TLR7/8 are localized to 
intracellular vesicles, where they recognize viral double-stranded RNA and single-stranded 
RNA, respectively (66, 194, 206).  TLR2 and TLR4 are localized to the cell surface, where 
they recognize viral structural proteins, along with bacterial PAMPs (reviewed in (146)).  
MyD88 is the essential adaptor protein required for TLR signaling through all of the TLRs, 
except for TLR3 and the MyD88-independent pathway of TLR4 signaling, both of which can 
signal via the adaptor Toll/IL-1R domain-containing adaptor inducing IFN-β (TRIF, also 
known as Ticam-1) (52, 146, 147, 207, 232, 267, 343).   
The RLRs: melanoma differentiation-associated gene (Mda)5 and retinoic acid-
inducible gene (RIG)-I, are localized to the cytoplasm, and recognize specific RNA motifs 
within viral RNA such as 5’ triphosphates on uncapped RNA and dsRNA (132, 144, 145, 
193, 244).  Once activated, the RLRs undergo a conformational change that allows them to 
bind via a caspase recruitment domain (CARD) to Interferon promoter stimulator (IPS)-1 
(also known as Cardif, Visa, and MAVS) which is located on mitochondria-associated 
membranes (131, 167). 
The ligation of PRRs results in the activation of latent transcription factors interferon 
regulatory factor (IRF)-3, IRF-7, and NF-κB, which in turn induce IFN, hundreds of 
interferon-stimulated genes (ISGs), along with inflammatory cytokines (reviewed in (52, 
128)).  To date, a number of specific anti-SINV ISGs have been identified, including the 
ubiquitin-like ISG15, Viperin, ISG12, ISG20, ZAP, and double-stranded RNA dependent 
protein kinase (PKR) (20, 94, 181, 181, 183, 199, 262, 349).  PKR is unique amongst these in 
that it is also a PRR, recognizing short stem-loops within RNA in an RLR-independent 
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manner, and upon activation, PKR activates IRF-3 and induces the phosphorylation of eIF2α, 
which inhibits host and certain viral translation and activates the host stress response (223).   
Despite the wealth of known host factors that inhibit SINV, the precise alphavirus 
PAMPs and cognate host PRRs required for IFN-α/β production in vitro and in vivo have not 
been fully elucidated, and the role of these molecules in the pathogenesis of neurovirulent 
SINVs has not been determined.  Type I IFN induction by SINV in primary murine fibroblast 
cells was shown to be largely dependent on PKR and Mda5 (35), however Mda5 was not 
required for SINV-induced IFN-α production in primary bone-marrow derived macrophages 
(97).  Recently, IPS-1 was shown to be critical for activation of IRF3 and IFN-α/β 
production in fibroblasts in a related alphavirus, chikungunya virus (CHIKV) (337).  
However, IPS-1 deficient mice were only slightly more susceptible to CHIKV peripheral 
infection, and exhibited increased CHIKV replication in the serum at 48 hours pi, but not in 
other organs or at other time-points (273).  A study with another neurotropic virus, West Nile 
virus, demonstrated that IPS-1 is essential for the regulated activation of the innate and 
development of the adaptive immune response (296).   
Given that the nsP1 T538I virulence determinant modulates IFN-α/β induction, we set 
out to determine whether viral interactions with specific IFN-α/β induction pathways were 
important for regulating viral neurovirulence.  To define the pathway(s) of innate immune 
activation by nsP1 T538I, we directly compared S300 to nsP1 T538I i.c. infection in mice on 
the C57BL/6J background deficient for IFN-α/β receptor (IFN-α/βR), MyD88, TRIF, and 
IPS-1.  The studies herein demonstrate that in the complete absence of IFN-α/β signaling, the 
attenuated virus regains virulence comparable to S300, suggesting that the attenuating 
mutation interacts with the type I IFN system to regulate virulence in vivo.  We find that the 
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IPS-1 signaling pathway plays a major role in controlling the attenuated nsP1 T538I virus 
and limiting virus-induced morbidity and mortality.  Furthermore, we demonstrate that while 
the TLR pathways are dispensable for nsP1 T538I replication control, TLR signaling via the 
TRIF adaptor molecule and not MyD88 may modulate the neurovirulence of SINV.   
 
2.2 Materials and Methods 
 
Mice.  Female C57BL/6J, TRIF/Ticam-1 deficient (stock 005037), and MyD88 
deficient (stock 009088) mice were obtained commercially from Jackson Labs.  IFN-α/βR-/- 
mice on the C57BL/6J background were provided by Jason Whitmire (UNC-Chapel Hill), 
and were originally made by Jonathan Sprent (The Scripps Research Institute) (163).  IPS-1-/- 
(STI) mice were generated in the Gale laboratory as previously described (65).  Mice were 
genotyped and bred in-house under specific-pathogen-free conditions.  Adult 9-12-week-old 
female mice were anesthetized with a ketamine-xylazine mixture prior to intracranial (i.c.) 
inoculation with 103 PFU of virus in diluent (Dulbecco’s Phosphate Buffered Saline [1X 
DPBS; GIBCO] supplemented with 1% donor calf serum (DCS), 0.122 mg/mL CaCl2, and 
0.10 mg/mL MgCl); total volume, 10µl).  Mock-infected mice received diluents alone.  Mice 
were weighed daily and monitored for disease signs.  As required by the UNC-CH 
Institutional Animal Care and Use Committee (IACUC), infected mice were euthanized 
during the experiment either when mice dropped below 70% of initial body weight or when 
mice exhibited severe disease signs.  Mouse experiments were approved and performed in 
accordance with all IACUC guidelines.   
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Viral burden analysis.  For in vivo growth studies, mice were inoculated as above 
and sacrificed by exsanguination followed by perfusion with 15 ml of PBS.  Indicated tissues 
were removed, weighed, homogenized using glass-beads in a tissue homogenizer and stored 
at -80˚C until viral load was assessed by a standard plaque assay on baby hamster kidney 
(BHK-21) cells as previously described (122). 
Virus production. The wild-type AR86 infectious clone is denoted as S300, and the 
mutant virus with a single amino acid change (nsP1 T538I) is denoted as S340.  Both pS300 
and pS55 plasmids, which differ only in the linearization site used, each encode wild-type 
AR86; thus, S300 and the previously designated S55 (122, 123) are synonymous.  Similarly, 
S51 is synonymous with S340/nsP1 T538I (122, 297).  Virus stocks were made as described 
previously (122).  Briefly, viral cDNA plasmids were linearized with PmeI and used as 
templates for the synthesis of full-length transcripts by using SP6-specific mMessage 
Machine in vitro transcription kits (Ambion).  Capped, poly-adenylated transcripts were then 
electroporated into BHK-21 cells, and after 24 hours, supernatants were harvested, and 
clarified at 3,000 RPM for 15 minutes.  All virus stocks were titrated by plaque assay on 
BHK-21 cells. 
In situ hybridization.  Hybridizations were performed with a 35S-UTP-labeled 
AR86-specifec riboprobe derived from pDS-45.  Clone pDS-45 was constructed, linearized, 
and transcribed as described previously (122).  This riboprobe encodes the last 187 
nucleotides of the nsP4 gene, the 26S promoter region, and the first 209 nucleotides of the 
capsid gene.  A riboprobe specific for Epstein-Barr virus was used as a control probe for 
nonspecific binding.  The AR86 probe was hybridized to tissues from PBS-inoculated mice 
as an additional control for nonspecific binding.  The in situ hybridizations were performed 
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according to the method of Charles et al., (47) by using 25 µL of probe/slide at 5 x 104 
cpm/µL.   
Histological analysis.  Mock-infected or SINV-infected mice were sacrificed by 
exsanguination followed by perfusion with 15 ml of PBS, 4% paraformaldehyde (PFA), pH 
7.3.  Brains were embedded in paraffin and 10µm sections were prepared and stained with 
hematoxylin and eosin (H&E) by the UNC histopathology core facility.  Sections were 
analyzed using an Olympus BX61 microscope fitted with a QImaging RETIGA 4000R color 
camera for digital imaging.   
 Real-time PCR.  For SINV genome analysis, a TaqMan primer-probe set (designed 
with the Primer Express software) specific for the nsP3 and the E2 region of SINV were 
used. The primer and probe sequences for the TaqMan primer-probe set were as follows: 
nsP3:  forward primer, 5′ - ATATCGCCTCGTTCGACAAAA-3′; reverse primer, 5′- 
ACACCCAGGTCTTCCAAGATCA-3′; and probe, 5′- TATGGCGTTAACCGGCCT-3′, E2:  
forward primer, 5′ - CGCGGCCTGGTGTACAAC-3′; reverse primer, 5′- 
CCAAACGCTCCTGGTTTCA-3′; and probe, 5′- TGACTTTCCGGAATACGGA-3′. Brain 
RNA was isolated with an RNeasy Lipid Tissue Mini kit (Qiagen).  cDNAs were synthesized 
from mRNA by reverse transcription with the respective tagged primer.  RT-PCR (qRT-
PCR) was then performed with Prism 7000 real-time PCR system.  cDNA standard curves 
for the SINV genome and 26S RNA were generated to ensure optimal primer-probe 
efficiency and to assign relative genome and 26S RNA copy numbers to directly compare 
each sample.  
Statistical Analysis.  Differences in Kaplan-Meier survival curves were analyzed by 
Mantel-Haenszel test.  Weight loss curves across days were initially analyzed by MANOVA.     
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If overall differences were observed across weight loss curves, ANOVA and Tukey’s 
Honestly Significant Difference test were used to determine factors influencing weight-loss 
within a given day.  Survival curves and weight loss data were analyzed using the R 
statistical language (249), with the survival package for survival analysis.  For in vivo viral 
burden analysis, a two-way ANOVA, with Bonferonni correction was used to determine 
statistical differences.  Viral burden data were analyzed using Prism software (GraphPad 
Prism5, San Diego, CA).     
 
2.3 Results 
 
A threonine at nsP1 position 538 is a critical determinant of SINV 
neurovirulence. The S300 strain of SINV is highly neurovirulent in adult mice, (122, 291) 
and we have previously identified four viral genetic determinants that regulate 
neurovirulence (297).  One of these determinants, a Thr codon at nsP1 position 538, is 
essential for S300 neurovirulence, where an attenuating Ile at this position decreases viral 
neurovirulence without adversely affecting viral replication in vitro or the ability of the virus 
to establish infection within the CNS (122).  Previous studies with this attenuated mutant 
were conducted in outbred CD-1 mice. However, to further analyze how this virus interacts 
with the host immune response, we confirmed that the nsP1 T538I mutant exhibits an 
attenuated phenotype after infection of inbred C57BL/6J mice.  As shown in Fig. 2.1A, 
infection of female adult C57BL/6J mice with S300 resulted in 100% lethality with a median 
survival time (MST) of 6.5 days (n=49) post i.c. inoculation.  Infection with nsP1 T538I 
resulted in 62.5% mortality and an increased MST of 9.5 dpi (n=56) (Fig. 2.1A and Table 
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2.1).    Moreover, S300 infected C57BL/6J mice displayed enhanced weight loss from 4-7 
dpi as compared to nsP1 T538I infected mice.  C57BL/6J mice infected with nsP1 T538I 
began to regain weight on day 9 dpi, while S300 infected mice never showed signs of weight 
gain/recovery (Fig. 2.1B).  Therefore, although the attenuated mutant caused more severe 
disease in the C57BL/6J background than was previously reported in outbred CD-1 mice, the 
mutant virus is still significantly attenuated in C57BL/6J mice when compared to S300 virus 
(Fig. 2.1).  Further analysis indicated that the nsP1 T538I virus replicated equivalently to 
S300 virus at 1 and 3 dpi within the CNS, however nsP1 T538I titers were significantly 
reduced as compared to S300 in the brain on 5 and 6 dpi, and in the spinal cord on day 6 pi 
(Fig. 2.1C and D).  These results suggest that the nsP1 538 virus is able to efficiently 
establish infection within the CNS, but that the virus is likely cleared more efficiently than 
S300.   
The nsP1 T538I displays comparable virulence to S300 in the absence of a 
functional type I IFN system. We have previously demonstrated that nsP1 T538I induces 
higher amounts of IFN-α/β compared to S300 in the serum of infected CD-1 and C57BL/6J 
mice and in cell culture (56).  Therefore to evaluate whether the mutant virus would regain 
wild-type virulence in the absence of IFN-α/β signaling we infected IFN-α/βR deficient mice 
with either S300 or nsP1 T538I.  Consistent with previous studies (260), IFN-α/βR-/- mice 
were highly susceptible to infection with SINV, and exhibited rapid and equivalent mortality 
and weight loss upon infection with either S300 or nsP1 T538I viruses (Fig. 2.2A and B).  
Specifically, infection of IFN-α/βR-/- mice with either the nsP1 T538I mutant or S300 
resulted in 100% mortality and a MST of 3.5 dpi (Fig. 2.2A and Table 2.1, 2.2).  
Furthermore, both S300 and nsP1 T538I replicated approximately 3 logs higher within the 
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brain and spinal cord of IFN-α/βR-/- mice as compared to C57BL/6J mice on day 3 pi (Fig. 
2.2C and D).  These data demonstrate that the mutant virus displays virulence comparable to 
S300 in the absence of type I IFN signaling.  When combined with our previous in vitro and 
in vivo studies (56), this observation suggests that interactions with the type I IFN system 
contribute to the attenuation of the nsP1 T538I mutant in vivo, and contribute to overall 
protection from S300 and nsP1 T538I induced disease.    
MyD88-dependent TLR signaling is dispensable for protection and control of 
nsP1 T538I.  Given that the nsP1 T538I mutant exhibited similar levels of virulence as S300 
in IFN-α/βR-/- mice, we sought to determine which type I IFN induction pathway(s) was 
responsible for regulating the attenuation of the nsP1 T538I mutant.  Therefore, we assessed 
the role of the TLR and RLR-mediated type I IFN induction pathways in the virulence of 
S300 and nsP1 T538I.  
To begin to assess the role of the TLRs in mediating type I IFN induction, we took 
advantage of the fact that there are a limited number of adaptor molecules that regulate 
signaling by TLRs: Myd88 (6) and TRIF.  To first assess the role of the MyD88-dependent 
TLRs, we infected C57BL/6J and MyD88-/- mice i.c. with 103 PFU of S300 or nsP1 T538I.  
As shown in Fig. 2.3A and B and Table 2.1, 2.2 , the attenuation of nsP1 T538I as compared 
to S300 in MyD88-/- mice was comparable to C57BL/6J mice, as measured by survival, MST, 
and weight loss, indicating that the MyD88-dependent TLRs do not contribute to the 
attenuation of the nsP1 T538I virus in vivo .  Furthermore, MyD88 signaling was not 
required for the control of replication of the nsP1 T538I virus in the brain (Fig. 2.3C) or 
spinal cord (Fig. 2.3D) at day 5 pi, the time-point at which control of nsP1 T538I is first 
detectable in C57BL/6J mice.  In addition, the attenuated nsP1 T538I virus phenotype was 
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maintained in TLR7-/- mice (data not shown), thus confirming the MyD88 result, and ruling 
out a specific role for TLR7.    Taken together, these data indicate that MyD88-dependent 
TLR signaling does not contribute to the attenuation of the nsP1 T538I virus.   
TRIF-dependent TLR signaling is not required for nsP1 T538I replication 
control, but does contribute to protection from virus-induced disease during SINV 
infection.  In order to evaluate the role of TRIF-dependent signaling in the pathogenesis of 
S300 or the nsP1 T538I mutant, we infected C57BL/6J and TRIF-/- mice with S300 or nsP1 
T538I and measured survival and weight loss, as well as virus-induced pathology and viral 
burden within the brain and spinal cord.  In contrast to our findings with MyD88, TRIF-/- 
mice exhibited a moderate increase in susceptibility to both S300 and nsP1 T538I viruses 
compared to C57BL/6J mice (Fig. 2.4A, B, G).  TRIF-/- mice infected with S300 succumbed  
to disease with a slightly more rapid MST of 6.25 dpi, as compared to 7 dpi for  S300 
infected C57BL/6J mice, while MSTs for the nsP1 T538I virus were reduced from 8.5 days 
in C57BL/6J mice to 7.5 days in TRIF-/- mice (Table 2-1, 2-2).  There is a trend towards 
decreased survival for TRIF-/- mice compared to C57BL/6J, which was significant for S300, 
while not significant for nsP1 T538I, though the pattern of increased mortality in TRIF-/- 
mice was repeatable in 3 independent experiments.  Analysis of weight loss following 
infection found that TRIF-/- mice infected with nsP1 T538I showed significantly enhanced 
weight loss as compared to C57BL/6J mice on 3-6 dpi (Fig. 2.4B).  These results suggest that 
TRIF does contribute to protection against virus-induced disease following both S300 and 
nsP1 T538I infection, though this effect was relatively modest.  Furthermore, since the nsP1 
T538I mutant did not show full restoration of virulence in TRIF-/- mice, these results suggest 
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that other IFN induction pathways also contribute to the attenuated phenotype of the nsP1 
T538I mutant.   
To further assess the role of TRIF in the pathogenesis of the nsP1 T538I virus, we 
evaluated viral loads within the CNS at day 5 pi.  Importantly, TRIF-/- animals showed 
similar levels of viral replication compared to C57BL/6J animals when infected with either 
S300 or nsP1 T538I.  By 5 dpi, nsP1 T538I viral titers in the brain were significantly lower 
than S300 titers (Fig. 2.4C), and were reduced (although not statistically significant) in spinal 
cords (Fig. 2.4D).  These results, which suggest that TRIF is not involved in the control of 
nsp1 T538I replication, were further supported by in situ hybridization for viral RNA within 
the CNS, where TRIF-/- mice were indistinguishable from C57BL/6J mice in terms of the 
distribution and intensity of viral RNA signal within the hippocampus (Fig. 2.4E) or brain 
stem (Fig. 2.4F) following infection with either S300 or the nsP1 T538I virus. 
Given that TRIF contributes to protection from virus-induced disease, but does not 
affect either viral loads or viral distribution within the CNS, we assessed whether TRIF 
deficiency might lead to enhanced pathology within the CNS of mice infected with either the 
S300 or nsP1 T538I viruses.  As shown in Fig. 2.4G, S300 infection resulted in neuronal 
dropout within the hippocampus of C57BL/6J mice, and this was unchanged in TRIF-/- 
animals.  Notably, although the nsP1 T538I virus caused little damage within the 
hippocampus of C57BL/6J mice, we report enhanced neuronal dropout in TRIF-/- mice, 
which further suggests that TRIF plays a protective role during nsP1 T538I infection.   
IPS-1 is required for control of CNS replication and protection upon nsP1 T538I 
infection.  Since TRIF-dependent signaling could not fully explain the attenuated phenotype 
of the nsP1 T538I virus, we next evaluated whether the cytoplasmic RLR pathway, which is 
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dependent upon the adaptor molecule IPS-1, was required to control the nsP1 T538I virus 
within the CNS.  In contrast to the MyD88-/- and TRIF-/- mice, the nsP1 T538I virus exhibited 
nearly complete restoration of virulence in the IPS-1-/- animals, with both the wild-type S300 
and nsP1 T538I viruses having nearly identical survival curves (Fig. 2.5A, Table 2.1, 2.2).  
Survival curve analysis indicates two important points: (1) the survival curve of S300 is not 
significantly different from that of nsP1 T538I in IPS-1-/- mice, and (2) both viruses cause 
more rapid   death in IPS-1-/- mice compared to C57BL/6J mice.  The MSTs of C57BL6/J 
mice infected with S300 or nsP1 T538I were 6 and 8.75 dpi, respectively.  However, IPS-1-/- 
mice show similar MSTs when infected with S300 or nsP1 T538I (5 and 5.5 dpi, 
respectively), suggesting that IPS-1-dependent signaling is required for protection from nsP1 
T538I virus infection (Table 2-1, 2-2).  We next assessed the role of IPS-1 in modulating 
weight loss of S300 and nsP1 T538I infected mice by statistically evaluating infected IPS-1-/- 
and C57BL/6J mice from days 0-5 pi (Fig 2.5B). While there were no differences in weight 
loss from 0-3 dpi, on day 4 pi S300 and nsP1 T538I infected IPS-1-/- mice exhibited 
significantly different percentages of weight loss.  This was also true for day 5 pi, though 
with the caveat being that day 5 pi data is censored due to death.   
To determine the role of IPS-1 in regulating viral replication in the CNS, viral burden 
was assayed in the brain and spinal cord on 1, 3, and 5 dpi.  There were no differences 
between host genotypes or virus genotypes at 1 dpi.  At 3 dpi, both viruses replicated to 
significantly higher levels in the brains and spinal cords of IPS-1-/- mice as compared to 
C57BL/6J animals (Fig. 2.5C and D).  On day 5 pi, the nsP1 T538I virus replicated to 
significantly higher levels within the brain and spinal cords of IPS-1-/- mice compared to 
C57BL/6J animals, suggesting that IPS-dependent signaling is at least partially responsible 
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for the faster clearance of the nsP1 T538I mutant.  However, nsP1 T538I titers were not fully 
restored to the levels of S300 in IPS-1-/- mice, indicating that other IFN signaling pathways 
also contribute to viral control.  These results were confirmed by virus-specific real-time 
PCR, where levels of nsP1 T538I viral genomic and 26S RNA within the brains and spinal 
cords were significantly increased in IPS-1-/- mice compared to C57BL/6J mice (Fig. 2.6A 
and B).  Furthermore, the nsP1 T538I virus exhibited stronger intensity and more broadly 
distributed viral signal within the CNS of IPS-1-/- mice compared to C57BL/6J animals, 
further suggesting that IPS-1 plays a major role in limiting nsP1 T538I replication at late 
times pi.  However, the fact that the mutant virus did not achieve the same level of 
replication as S300 in IPS-1-/- animals suggests that other IFN induction pathways may act in 
concert with IPS-1 to control the nsP1 T538I mutant.   
To further assess the impact of IPS-1 deficiency on protection from nsP1 T538I-
induced disease, we compared damage and inflammation in C57BL/6J mice and IPS-1-/- mice 
following S300 or nsP1 T538I infection.  In C57BL/6J mice, S300 caused more severe 
neuronal damage within the hippocampus at 5 dpi than the nsP1 T538I virus.  However, in 
IPS-1-/- mice both viruses caused severe damage to neurons in the hippocampus (Fig. 2.6E) 
and cortex (data not shown), with pyknotic neurons and significant neuronal dropout with 
both viruses (Fig. 2.6E).   
 
2.4 Discussion 
 
The type I IFN system plays an essential role in the control and tropism of many 
viruses including alphaviruses (55, 82, 259-261, 338, 338).  As a result, alphaviruses have 
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evolved mechanisms to avoid or actively suppress the type I IFN system, and thus this 
interplay between virus and host likely have major impacts on the outcome of disease.  
Previous work from a number of groups has demonstrated that alphaviruses, including SINV, 
avoid IFN-α/β induction at least in part through their ability to nonspecifically shutoff host 
RNA and protein synthesis (3, 83, 85, 309).  Recent studies with several different 
alphaviruses, including Semliki Forest virus, CHIKV, Venezuelan equine encephalitis virus, 
and SINV, indicate that these viruses are able to modulate IFN-α/β induction and signaling 
independently of host cell shutoff (26, 56, 86, 288, 289).  In the context of SINV infection, 
our research group has demonstrated that a determinant at nsP1 position 538 of the 
neurovirulent AR86 strain of SINV modulates both IFN-α/β induction (56) and IFN-α/β-
induced Jak/STAT signaling (289), in a host shutoff independent manner.  Importantly, this 
determinant at nsP1 538 also plays a major role in neurovirulence, where the presence of the 
nsP1 538 Ile is also severely attenuating for S300 neurovirulence (122, 123, 297).  Therefore, 
we set out to determine whether the type I IFN system was required for the attenuated 
phenotype of the nsP1 T538I mutant in vivo, and if so, which host sensing pathway or 
pathways contributed to this phenotype.  These studies clearly demonstrate that in the 
absence of a functional type I IFN system, the attenuated mutant is as virulent as wild-type 
S300, and that both viruses cause more severe disease.  In addition, the IPS-1-dependent host 
sensing pathway, and to a lesser extent, the TRIF-dependent signaling pathways contribute to 
this phenotype.   
To our knowledge, this is the first time that IPS-1-dependent signaling has been 
linked to the control of a neurovirulent alphavirus.  Despite the critical role of IPS-1, it does 
not explain all of the protection and replication control provided by type-I interferon, because  
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IFN-α/βR-/- mice succumbed to infection approximately 2 days before IPS-1-/- mice, and IFN-
α/βR-/- supported approximately 1.5 logs greater replication in the CNS, than did IPS-1-/- 
mice at 3 dpi.  Our results are consistent with those of several other groups that have 
demonstrated that the cytoplasmic RNA sensing pathways play a major role in the response 
to alphaviruses.  IPS-1-dependent signaling pathways have been shown to play a major role 
in IFN-α/β induction by SINV (35) and CHIKV (337), (273).  In vivo studies demonstrated 
that IPS-1-/- mice support increased CHIKV replication in the serum at 48 hpi, but not in 
other organs or at other time-points tested (273).   While no IPS-1-/- mice died from infection 
with CHIKV, 100% of IFN-α/βR-/- mice infected with CHIKV died within 4 dpi (273).   
Another study report that during poliovirus (PV) infection, the TLR3-TRIF mediated 
response was the dominant protective response; however MyD88-/- mice were also more 
susceptible PV (2).  Thus, the studies herein are not the first to report roles for two host 
sensing pathways in vivo.   
Based on the critical protective role for IPS-1 in nsP1 T538I pathogenesis, we are 
currently assessing the roles of RIG-I and Mda5 in sensing the nsP1 T538I mutant. We have 
previously shown that the nsP1 T538I mutation leads to enhanced 26S RNA synthesis (123). 
Since RIG-I and Mda5 recognize viral RNA the nsP1 T538I virus may be producing more 
ligand in virally infected cells compared to wild-type S300.   Studies are currently underway 
to evaluate whether enhanced 26S RNA expression or some other aspect of the nsP1 T538I 
mutant virus life cycle leads to enhanced type I IFN induction via IPS-1, TRIF, or 
interactions between the two pathways compared to wild-type S300.  Furthermore, we have 
demonstrated that TLR4 is not required for protection from nsP1 T538I disease, suggesting 
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that TLR3-dependent signaling may be responsible for the protective role of TRIF 
(Supplemental Fig 2.1).  TLR3-/- mice are currently being tested.    
A recent study with CHIKV reported a role for MyD88 in controlling viral replication 
and dissemination (273), suggesting that TLR-dependent signaling pathways can control 
alphavirus replication and could also contribute to the response to SINV strain AR86.  
However, we found no evidence that MyD88 was required for the control of or protection 
after i.c. infection with the nsP1 T538I mutant virus, as the nsP1 T538I virus still exhibited 
an attenuated phenotype and enhanced clearance compared to the S300 in mice lacking 
MyD88.  This may reflect intrinsic differences in the control of CHIKV and AR86 or reflect 
differential host responses after peripheral infection (CHIKV) versus i.c. infection (AR86).  
One possible explanation for the differences in the role of TLRs and RLRs between 
SINV and CHIKV is that these viruses are infecting or responding to IFN-α/β in different cell 
types.  In support of this hypothesis, CHIKV did not infect or induce IFN-α/β in dendritic 
cells (DCs) (273), however, SINV has been shown to infect DCs (262) and SINV induces 
robust IFN-α/β in primary bone-marrow derived DCs and macrophages (unpublished results).  
Moreover, CHIKV primarily infects nonhematopoietic cells, such as fibroblasts, which can 
produce IFN-α/β (273), although CHIKV was capable of infecting and persisting in 
macrophages in a nonhuman primate model (169).  Future work should address how 
differences in interactions with the IFN-α/β pathway may regulate SINV and CHIKV tropism 
and disease outcome in vivo.   
Type I IFNs can exert antiviral effects through direct induction of ISGs with intrinsic 
antiviral activity or by stimulating the adaptive immune response (54, 78, 119, 248).  Several 
ISGs have been shown to contribute to alphavirus control, and future studies will address 
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whether IPS-1-dependent expression of these or other ISGs exert antiviral activity against the 
nsP1 T538I virus.  Adaptive immune pathways, namely antibody, IFN-γ, and T cells, also 
play key roles in SINV control and clearance (21, 32, 33, 37, 104, 110).  IPS-1 has 
previously been shown to modulate the adaptive immune response during West Nile virus 
infection (296), and thus it will also be important to determine if IPS-1-signaling contributes 
to virus-specific T cell or antibody responses to nsP1 T538I.  Evidence has shown that IPS-1 
and TRIF cooperatively contribute to the adjuvant effects of poly I:C, a result that was only 
determined by examining the IPS-1 and TRIF double-knockout mouse (168).  While we have 
shown the independent roles of the TLR and RLR pathways, studies are underway to test 
how these pathways can cooperatively interact.    
In summary, we have demonstrated that the type I IFN pathway via IPS-1, but not 
TLR-dependent signaling pathways are essential for controlling the nsP1 T538I mutant.  
Furthermore, IPS-1, and to a lesser extent, TRIF-dependent signaling protected from nsP1 
T538I induced disease.  These studies suggest that the in vivo attenuation of the nsP1 T538I 
virus is predominantly regulated by the IPS-1-dependent sensing pathway.  
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Figure 2.1:  The mutant virus nsP1 T538I is attenuated in C57BL/6J mice as compared 
to S300 wild-type virus.   
A)   
 
 B) 
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Figure 2.1:  The mutant virus nsP1 T538I is attenuated in C57BL/6J mice as compared 
to S300 wild-type virus.  Adult 9-12-week-old female C57BL/6J mice were infected i.c. 
with 103 PFU of S300 or nsP1 T538I virus and monitored daily for (A) survival, (B) weight 
loss, and (C) brain and (D) spinal cords were harvested at 1, 3, 5, and 6 days post infection 
for viral titer by plaque assay.  Survival data are presented as the pooled results of at least 3 
experiments.   Weight loss data are presented as the means + the standard deviation of 16 
experiments.  Viral titer data are shown as the mean of a single experiment and are 
representative of at least three experiments.  The number of mice infected per virus is 
indicated in parentheses.  Asterisks denote p < 0.01(**), p < 0.001(***), or p < 
0.0001(****).  The horizontal dashed line indicates the lower limit of assay sensitivity.   
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Figure 2.2:  Both S300 and nsP1 T538I show equivalent and enhanced virulence in the 
absence of the IFN-α/β response.   
A)  
 
B)   
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Figure 2.2:  Both S300 and nsP1 T538I show equivalent and enhanced virulence in the 
absence of the IFN-α/β response.  Adult 9-12-week-old female C57BL/6J and IFN-α/βR 
deficient mice were infected i.c. with 103 PFU of S300 or nsP1 T538I virus.  Equivalent and 
rapid (A) lethality and (B) weight loss with both S300 and nsP1 T538I infection of IFN-
α/βR-/- mice.  The number of mice infected per virus is indicated in parentheses, and data are 
compiled from a minimum of two experiments.  Infectious virus data are shown as the mean 
of 2 pooled experiments, and was assayed at day 3 pi within the (C) brain and (D) spinal cord 
of C57BL/6J and IFN-α/βR-/- mice.  Asterisks denote p < 0.0001(****).  The dashed line 
indicates the lower limit of assay sensitivity.   
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Figure 2.3:  TLR signaling through MyD88 is not required for protection or control of 
nsP1 T538I infection.  
A)  
 
B)  
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Figure 2.3:  TLR signaling through MyD88 is not required for protection or control of 
nsP1 T538I infection. Adult 9-12-week-old female C57BL/6J and MyD88-/- mice were 
infected i.c. with 103 PFU of S300 or nsP1 T538I virus.  Differential (A) survival and (B) 
weight loss between S300 and nsP1 T538I infected MyD88-/- mice. The number of mice 
infected per group is indicated in parentheses.  Infectious virus was assayed at 5 days pi in 
the (C) brain and (D) spinal cord.  Asterisks denote p < 0.01(**) or p < 0.001(***).  Titer 
data are representative of two or more experiments.  The dashed line indicates the lower limit 
of assay sensitivity.   
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Figure 2.4:  TRIF signaling is not required for viral replication control of nsP1 T538I, 
but TRIF may play a minor role in protection from SINV-induced disease. 
A) 
 
B) 
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Figure 2.4:  TRIF signaling is not required for viral replication control of nsP1 T538I, 
but TRIF may play a minor role in protection from SINV-induced disease.  Adult 9-12-
week-old female C57BL/6J and TRIF-/- mice were infected i.c. with 103 PFU of S300 or nsP1 
T538I virus.  (A) Survival and (B) weight loss of S300 and nsP1 T538I infected C57BL/6J or 
TRIF-/- mice are shown.  The number of mice infected per group is indicated in parentheses.  
Infectious virus was assayed at 5 days pi within the (C) brain and (D) spinal cord.  Titer data 
are representative of two or more experiments.  Asterisks denote p < 0.05(*) or p < 0.01(**).  
The dashed line indicates the lower limit of assay sensitivity.  Mice were perfused with 15 
mL of 4% PFA for in situ hybridization and H&E, and brains were paraffin embedded and 
cut sagitally. Sections were subjected to in situ hybridization with a riboprobe specific for 
SINV AR86 and shown are (E) hippocampus and (F) spinal cord regions. Nonspecific 
binding controls included sections from mock-infected mice probed with the AR86 
riboprobe, and sections from infected mice probed with a riboprobe specific for Epstein-Barr 
virus (not shown).  (G) H&E stained brain sections depicting the hippocampus.   
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Figure 2.5:  IPS-1 is required for protection from nsP1 T538I and contributes to control 
of nsP1 T538I.  
A) 
 
B)  
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Figure 2.5:  IPS-1 is required for protection from nsP1 T538I and contributes to control 
of nsP1 T538I.  Adult 9-12-week-old female C57BL/6J and IPS-1-/- mice were infected i.c. 
with 103 PFU of S300 or nsP1 T538I virus.  Similar (A) survival and (B) weight loss curves 
between S300 and nsP1 T538I infected IPS-1-/- mice.  The number of mice infected per 
group is indicated in parentheses.  Infectious virus was assayed at 1, 3, and 5 days pi in the 
(C) brain and (D) spinal cord. Titer data are representative of two or more experiments.  
Asterisks denote p < 0.05(*), p < 0.01(**), p < 0.01(***), and p < 0.0001(****). The dashed 
line indicates the lower limit of assay sensitivity.   
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Figure 2.6: Increased quantity and distribution of viral RNA and neuronal damage in 
IPS-1-/- mice infected with S300 and nsP1 T538I as compared with C57BL/6 mice 
infected with nsP1 T538I.  
A)   
 
B) 
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Figure 2.6: Increased quantity and distribution of viral RNA and neuronal damage in 
IPS-1-/- mice infected with S300 and nsP1 T538I as compared with C57BL/6 mice 
infected with nsP1 T538I.  C57BL/6J and age-matched IPS-1-/- mice were infected i.c. with 
103 PFU of S300 or nsP1 T538I virus.  Brains were harvested at 5 days pi. (A,B)  Mice were 
perfused with 15 mL of PBS, and RNA was harvested prior to qRT-PCR using primer/probe 
sets specific for SINV (A) 49S genomic RNA or (B) 26S subgenomic RNA.  Asterisks 
denote p < 0.05(*), p < 0.01(**), p < 0.001(***), or p < 0.0001(****).  Mice were perfused 
with 15 mL of 4% PFA for in situ hybridization and H&E, and brains were paraffin 
embedded and cut sagitally.   Sections were subjected to (C, D) in situ hybridization with a 
riboprobe specific for SINV AR86 or (E) H&E.  Nonspecific binding controls included 
sections from mock-infected mice probed with the AR86 riboprobe, and sections from 
infected mice probed with a riboprobe specific for Epstein-Barr virus (not shown).  Data 
shown are representative of three experiments with at least three mice per group. 
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Table 2.1:  Percent mortality and median survival times after S300 or nsP1 T538I i.c. 
infection of C57BL/6J mice and each knockout mouse line. 
 
aValues are pooled across all experiments.  
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Table 2.2:  Statistical differences in survival curves within each knockout mouse strain 
after S300 or nsP1 T538I i.c. infection.   
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Supplemental Figure 2.1:  TLR4 signaling is dispensable for conferring the attenuated 
phenotype during nsP1 T538I infection.   
A) 
 
B) 
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Supplemental Figure 2.1:  TLR4 signaling is dispensable for conferring the attenuated 
phenotype during nsP1 T538I infection.  Adult 9-12-week-old female C57BL/6J and 
TLR4-/- mice were infected i.c. with 103 PFU of S300 or nsP1 T538I virus.  Similar (A) 
survival and (B) weight loss curves between S300 and nsP1 T538I infected TLR4-/- mice.  
The number of mice infected per group is indicated in parentheses.   
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CHAPTER THREE: 
 
ADAPTIVE IMMUNITY CONTRIBUTES TO PROTECTION FROM SINDBIS-
INDUCED NEUROLOGIC DISEASE 
 
3.1 Introduction 
 
Sindbis virus (SINV) is a positive-sense single-stranded RNA virus within the genus 
alphavirus that alternates between a mosquito and vertebrate host in nature.  There are two 
classes of alphaviruses, namely the Old World alphaviruses, such as chikungunya (CHIKV), 
Ross River virus (RRV), and SINV that cause outbreaks of infectious arthritis, and the New 
World alphaviruses such as Venezuelan equine encephalitis virus (VEEV) and eastern equine 
encephalitis (EEEV) that cause outbreaks of encephalitis.  Pathogenic alphaviruses pose a 
substantial public health threat that necessitates improved understanding and design of 
effective therapeutics.  Mouse models of alphavirus encephalitis have provided valuable 
insights into the virus and host contributions to disease, and the studies herein will focus on 
the role of adaptive immunity during SINV-induced encephalomyelitis in mice.All SINVs 
are avirulent in adult mice, with notable exceptions being neuro-adapted SINV (NSV) (111),
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AR86 (hereafter referred to as the infectious clone S300) (291), and SVNI (198).  S300 is 
highly neurovirulent, and  i.c. infection of adult mice results in 100% mortality within 5 to 8 
dpi, with neurologic symptoms including hind and forelimb paralysis, seizures, and 
conjunctivitis evident (122, 124).  While NSV genetic determinants of disease lie within E2, 
AR86 contains three genetic determinants of disease that lie within the nonstructural proteins 
(nsPs), plus an additional determinant within E2 (298).  Therefore AR86 provides a unique 
model to ask questions about how nsP attenuating mutations interact with the adaptive 
immune system.       
One critical determinant of S300 neurovirulence is at the C-terminus of nsP1 at 
position 538.  Introduction of an Ile at nsP1 position 538 in place of the wild type Thr 
(hereafter named nsP1 T538I) decreases mortality to 62.5% in mice (vs. 100% with wild type 
virus), increases production of type I IFN both in vitro and in vivo, and abrogrates the virus’s 
ability to specifically block Jak/STAT activation in vitro (122, 289, 297).  Moreover, control 
of virus replication and recovery upon infection with the nsP1 T538I mutant virus is 
dependent on both the IFN-α/β receptor and specifically RIG-I-like receptor (RLR) signaling 
via IPS-1 (submitted).  While IPS-1 likely controls nsP1 T538I replication at an early stage 
of infection, the studies herein address the contribution of the adaptive immune system to 
recovery and replication control of nsP1 T538I, and whether the innate immune system 
contributes to the development of a protective adaptive immune response.     
Components of the host adaptive immune response contribute to disease during 
murine infection with two encephalitic alphaviruses, NSV and wild type VEEV, the latter of 
which is the most intensively studied alphavirus.  During VEEV infection, CD8+ T cells, the 
activation of astrocytes, and the pro-inflammatory cytokines TNF-α, inducible nitric oxide 
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synthase (iNOS), interferon (IFN)-γ, interleukin (IL)-1, IL-6, and chemokines may contribute 
to the severity of encephalitis (46, 102, 275, 276, 284).  While local and systemic 
neutralizing antibodies are most critical for eliciting protection from wild type VEEV, T cells 
contribute to clearance of attenuated VEEV strains (30, 71).   
During NSV infection of adult mice, CD4+ T cells, IFN-γ, and TNF-α contribute to 
disease exacerbation (154, 255).  Furthermore, while both avirulent SVA SINV and 
neurovirulent SVNI SINV infect astroctyes in vitro, only SVNI activates astrocytes (29).  
However, during infection with avirulent SINV strains, antibody and IFN-γ act cooperatively 
to mediate noncytolytic clearance from neurons (21, 32, 33, 110).  Therefore, although 
adaptive immunity may play either a protective or pathologic role during SINV infection, it 
is clear that adaptive immunity plays a major role in regulating virus-induced disease.   
We and others have established an essential role for type I IFN in protection from 
alphavirus-induced neurologic disease.  However, prior to these studies, we did not 
understand the role of adaptive immunity during AR86 infection.  In addition, we determine 
whether intrinsic type I IFN response on lymphocytes contributes to the control of SINV in 
vivo.  These studies establish roles for B and T cells in driving control of the nsP1 T538I 
mutant, and suggest that IFN-γ may play a pathogenic role during AR86 infection of the 
CNS.    
 
3.2 Materials and Methods 
 
Mice.  Female C57BL/6J, RAG-1-/-, µMT, IFN-γ R-/- (RGKO), and IFN-γ-/- (GKO) 
mice were obtained commercially from Jackson Labs.  Mice were genotyped and bred in-
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house under specific-pathogen-free conditions.  Adult 9-12-week-old female mice were 
anesthetized with a ketamine-xylazine mixture prior to intracranial (i.c.) inoculation with 103 
PFU of virus in diluent (Dulbecco’s Phosphate Buffered Saline [1X DPBS; GIBCO] 
supplemented with 1% donor calf serum (DCS), 0.122 mg/mL CaCl2, and 0.10 mg/mL 
MgCl); total volume, 10µl).  Mock-infected mice received diluents alone.  Mice were 
weighed daily and monitored for disease signs.  As required by the UNC-CH Institutional 
Animal Care and Use Committee (IACUC), infected mice were euthanized during the 
experiment either when mice dropped below 70% of initial body weight or when mice 
exhibited severe disease signs.  Mouse experiments were approved and performed in 
accordance with all IACUC guidelines.   
Viral burden analysis.  For in vivo growth studies, mice were inoculated as above 
and sacrificed by exsanguination followed by perfusion with 15 ml of PBS.  Indicated tissues 
were removed, weighed, homogenized using glass-beads in a tissue homogenizer and stored 
at -80˚C until viral load was assessed by plaque assay on baby hamster kidney (BHK-21) 
cells as previously described (210).  Briefly, BHK-21 cells were seeded in 6-well plates ~24 
h prior to inoculation with 10-fold serial dilutions of viral samples.  After a 1h incubation, 
samples were overlayed with semi-solid carboxy methyl-cellulose, followed by incubation at 
37˚C for 38-44 h, fixed with 4% PFA, stained with crystal violet, and counted.   
Virus production. The wild-type AR86 infectious clone is denoted as S300, and the 
mutant virus with a single amino acid change (nsP1 T538I) is denoted as S340.  Both pS300 
and pS55 plasmids, which differ only in the linearization site used, each encode wild-type 
AR86; thus, S300 and the previously designated S55 (122, 123) are synonymous.  Similarly, 
S51 is synonymous with S340/nsP1 T538I (122, 297).  Virus stocks were made as described 
86 
 
previously (122).  Briefly, viral cDNA plasmids were linearized with PmeI and used as 
templates for the synthesis of full-length transcripts by using SP6-specific mMessage 
Machine in vitro transcription kits (Ambion).  Capped, poly-adenylated transcripts were then 
electroporated into BHK-21 cells, and after 24 hours, supernatants were harvested, and 
clarified at 3,000 RPM for 15 minutes.  All virus stocks were titrated by plaque assay on 
BHK-21 cells. 
Quantification of CNS leukocytes and flow cytometry. S300 and nsP1 T538I 
infected mice were sacrificed by exsanguination and perfused with PBS.  Brains and spinal 
cords were harvested, minced, and then incubated for 1.5 h with vigorous shaking at 37°C in 
digestion medium (RPMI medium, 1% fetal calf serum, 25 mM HEPES, 1.25 mg/ml 
collagenase A [Roche]). Homogenates were then passed through a 40-µm-pore-size strainer 
and pelleted through 25% Percoll (GE Healthcare) in medium (RPMI medium, 1% fetal calf 
serum, 25 mM HEPES) for 20 min at 800 x g. The resulting pellets were then resuspended in 
30% Percoll, overlaid above 70% Percoll, and centrifuged for 20 min at 800 x g.  The 
interface was collected and washed with media, and the absolute number of live cells in each 
sample was then determined by trypan blue exclusion. Cells were washed in flow cytometry 
wash buffer (1X Hanks’ balanced salt solution,1% fetal calf serum, 0.1% sodium azide) and 
then stained with the following antibodies: anti-CD45- phycoerithrin–Cy5 (anti-CD45-PE-
Cy5), anti-CD11b–phycoerithrin–Cy7 (anti-CD11b–PE–Cy7), anti-Ly6G PE (anti-Ly6G-
PE), anti-Ly6C-FITC, anti-CD11c-PE-Texas Red, anti-MHC class II-APC, and anti-B220 
eF780 (eBioscience).  In a separate panel the following antibodies were used:  anti-CD3-
FITC, anti-CD8-PerCP, anti-NK1.1-PE, anti-B220 Texas Red, anti-F4/80-PECy7, and anti-
CD49b-APC (eBioscience) and anti-CD4-Pacific Blue (Caltag). All staining was done in the 
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presence of anti-mouse FcγRII/III (clone 2.4G2; BD Pharmingen) to prevent nonspecific 
antibody binding. Following staining, samples were fixed in 2% paraformaldehyde–PBS and 
analyzed using a CyAn flow cytometer and Summit 5.2 software (Dako). Absolute numbers 
of each specific cell type were calculated by determining the total number of live cells within 
a sample by trypan blue exclusion and then multiplying that number by the percentage of live 
cells within the sample bearing the appropriate surface staining profile. 
Reconstitution of RAG-1-/- mice.  Whole splenocyte suspensions were prepared 
from spleens of C57BL/6J or IFN-α/β R-/- mice.  Splenocytes were removed by blunt 
dissection and passed through a 70-µm pore size filter, followed by centrifugation and red 
blood cell lysis.  Splenocytes were counted and resuspended in RPMI medium.  
Approximately 2 x 108 splenocytes were injected intra-orbitally into RAG-1-/- mice at 4 and 1 
days prior to infection.   
Enzyme-Linked Immunosorbent Assay (ELISA).  To produce SINV antigen, 
AR86 virus was produced as described in the previous section, and concentrated through a 5 
ml cushion of 20% sucrose in PBS at 24K at 4˚C for 4 h in a Sorvall.   To remove sucrose, 
the resuspended pellet was further concentrated by Microcon centrifical filter (Millipore) 
centrifugation.  ELISA was performed as previously described (63).  For titration of SINV-
specific antibody isotypes in mouse serum, ELISAs were performed with horseradish 
peroxidase (HRP)-conjugated rabbit anti-mouse IgG, IgM, IgG1, or IgG2c and the 
peroxidase substrate o-phenylenediamine dihydrochloride (OPD).  The optical density (OD) 
at 450 nm was measured (plate reader).  Log10 half-maximum ELISA titers were calculated 
with Sigmaplot (Systat [http://www.systat.com]) using the solution of the sigmoidal line of 
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the plot of the log of the reciprocal dilutions of mouse sera and the resulting absorbances to 
determine the log of the reciprocal dilution at which an absorbance of 2.1 was achieved. 
Plaque reduction neutralization titers assays.  Mouse serum was heat inactivated at 
55˚C for 30 min and then serially diluted in 2-fold starting at 1:50.  Each diluted serum 
sample was mixed 1:1 with 100 PFU of S300 and incubated at 37˚C for 1 h.  Next, the 
serum-virus mixture was added in duplicate to Vero monolayers.  After a 1 h infection, 
monolayers were overlayed with semi-solid carboxy methyl-cellulose, followed by 
incubation at 37˚ C for 48 h, fixed with 4% PFA, stained with crystal violet, and counted.  
The 50% plaque reduction neutralization titer (PRNT50) values were determined as the serum 
dilutions at which plaque numbers were reduced by 50% relative to that of virus treated with 
PBS alone.   
In vivo depletions.  C57BL/6J mice received i.p. injections of 0.5 mg of depletion 
antibody in 0.1 ml of PBS 24 h prior to infection, 24 h following infection, and every 72 h for 
the duration of the experiment.  The depleting antibodies used were 17A2 (αCD3), GK1.5 
(αCD4), 2.43 (αCD8), and LTF2 (isotype control) (all Bio X Cell).  At either 5 or 7 dpi, mice 
were exsanguinated, and brains and spinal cords were collected for viral burden analysis, and 
spleens were collected to determine depletion efficacy by flow cytometry.   
Primary astrocyte isolation.  Primary astrocytes were cultured from the cerebral 
cortices of 1-2 day-old mice, followed by trypsination for 25 minutes.  Cells were triturated 
through a 5 ml serological pipet and filtered through a 70-µm pore size filter.  Next, cells 
from 2 cortices were seeded on 75 cm2 culture flasks and incubated with 30 ml DMEM 
containing 10% FBS, 2mM L-glutamine, 1% penicillin/streptomycin, and Fungizone (0.25 
µg/ml, Invitrogen).  Medium was exchanged 24 h after seeding and every 48 h thereafter.  
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When cells reached confluency after 10-12 days, flasks were shaken at 250 rpm for 24 h to 
remove microglia.  The adherent cells were greater than % astrocytes, as measured by flow 
cytometry using Alexa Fluor 587 anti-GFAP and Alexa Fluor 488 anti-CD11b 
(eBiosciences).   
Real-time PCR.  Total RNA was extracted by using TRIzol and PureLink 
purification system (Invitrogen), and equivalent amount of total RNA were reverse 
transcribed by using SuperScript III and random primers according to the 
manufacturer’s instructions (Invitrogen).  cDNA was subsequently quantified by 
TaqMan real-time PCR using a Prism 7000 real-time PCR system (Applied Biosystems).  
For each sample, GAPDH (glyceraldehydes-3-phosphate dehydrogenase) levels were 
quantified to calculate relative gene expression of the gene of interest by using the 2ΔΔCT  
method.  The following primer-probe sets were used:  GAPDH (Mm99999915_g1), CXCL9 
(Mm01345159_m1), CXCL10 (Mm00445235_m1), CXCL11 (Mm0044662_m1), and NOS2 
(Mm00440485_m1).   
Statistical Analysis.  Differences in Kaplan-Meier survival curves were analyzed by 
Mantel-Haenszel test.  Weight loss curves across days were initially analyzed by MANOVA.     
If overall differences were observed across weight loss curves, ANOVA and Tukey’s 
Honestly Significant Difference test were used to determine factors influencing weight-loss 
within a given day.  Survival curves and weight loss data were analyzed using the R 
statistical language (249), with the survival package for survival analysis.  For in vivo viral 
burden analysis, a two-way ANOVA, with Bonferonni correction was used to determine 
statistical differences.  Real-time qPCR data were analyzed by Two-Way ANOVA with 
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Bonferonni correction.  Viral burden data were analyzed using Prism software (GraphPad 
Prism5, San Diego, CA).     
 
 
3.3 Results 
 
Similar composition of inflammatory cells in the CNS of S300 and nsP1 T538I 
infected C57BL/6J mice.   We have previously established a role for innate immunity in the 
control of the nsP1 T538I virus.  Therefore we were interested in determining whether other 
aspects of the host response, including virus-induced inflammation, might contribute to the 
attenuated phenotype of the nsP1 T538I virus.  We initially evaluated whether there were 
major differences in virus-induced inflammation within the CNS of adult mice infected 
intracranially (i.c.) with 103 PFU of either S300 or nsP1 T538I.  Inflammatory cell 
populations were quantified in the brain and spinal cord of C57BL/6J mice infected with 
S300 or nsP1 T538I viruses on day 5 pi.   
The total number of T cells, NK cells, B cells, inflammatory macrophages, or 
microglia were not different between viruses in either the brain or spinal cord (Fig 1. A-H).  
There was also no difference in the mean fluorescence intensity of MHC class II on 
microglia (data not shown).  However, based on these results alone, we cannot rule out the 
possibility that site-specific activation or recruitment of inflammatory cells differs in the 
CNS of S300 and nsP1 T538I infected mice.   
Adaptive immunity is required for replication control and recovery after nsP1 
T538I intracranial infection.  Since we observed no significant differences in inflammatory 
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cell infiltration within the CNS, we next evaluated whether specific aspects of the host 
adaptive immune response contributed to either the control of nsP1 T538I or the 
neurovirulence of S300.  Therefore, we tested whether RAG-1-/- mice, which lack functional 
T and B cell responses exhibited altered sensitivity to either S300 or nsP1 T538I.  All adult 
RAG-1-/- mice infected i.c. with 103 PFU of S300 or nsP1 T538I viruses succumbed to 
disease.  However, nsP1T538I remained attenuated in comparison to S300 within RAG-1-/- 
mice as measured by survival and weight loss (Fig. 3.2A and B).  Specifically, median 
survival times (MSTs) for S300 and nsP1 T538I infected C57BL/6J mice were 6.5 and 9.75 
dpi, respectively, while MSTs for S300 and nsP1 T538I infected RAG-1-/- mice were 6.25 
and 7.25 dpi, respectively.  Weight loss kinetics and survival curves were similar for S300 
infected C57BL/6J mice and RAG-1-/- mice, suggesting that adaptive immunity does not 
contribute to S300 induced disease.  However, because RAG-1-/- mice were incapable of 
surviving  nsP1 T538I infection, adaptive immunity is required for recovery after infection 
with the nsP1 T538I mutant.   
Next we investigated the role of T and B cells in modulating S300 and nsP1 T538I 
replication in the CNS.  Figure 3.2C and D illustrate that both viruses replicate equivalently 
in the CNS of C57BL/6J and RAG-1-/- mice on days 1 and 3 pi, with the exception of a day 3 
pi replication advantage of S300 within the brains of RAG-1-/- mice as compared to S300 
within C57BL/6J brains.  However, on day 5 pi, nsP1 T538I replicated equivalently to S300 
in the CNS of in RAG-1-/- mice, while age-matched C57BL/6J mice more efficiently 
controlled nsP1 T538I than S300 (Fig. 3.2C and D).   
B cells are critical for control but not clearance of nsP1 T538I and are not 
essential for survival.  To determine the individual contribution of B cells to the attenuation 
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of nsP1 T538I, µMT and C57BL/6J mice were infected with S300 or nsP1 T538I.  As 
observed in RAG-1-/- mice, survival curves, weight loss, and replication at 5 days pi after 
S300 infection was similar in µMT and C57BL/6J mice (Fig. 3.3A-D).  Interestingly, 25% of 
µMT mice recovered from nsP1 T538I infection (compared to 50% of C57BL/6J mice), 
demonstrating that while B cells likely contribute to survival after nsP1 T538I infection, they 
are not essential (Fig. 3.3A).  µMT mice infected with nsP1 T538I did exhibit increased 
mortality and delayed recovery as measured by weight gain compared to C57BL/6J mice 
infected with nsP1 T538I (Fig. 3.3A and B).  µMT mice failed to control nsP1 T538I 
replication in the brain or spinal cord at day 5 or 7 pi, however by day 15 pi nsP1 T538I was 
nearly undetectable in the CNS (Fig. 3.3C and D).   
T cells contribute to control of nsP1 T538I.  Since µMT mice did not recapitulate 
the entirety of the phenotype observed in RAG-1-/-, we hypothesized that T cells may also 
contribute to control and protection during nsP1 T538I infection.  To test the role of T cells 
in conferring control of nsP1 T538I, C57BL/6J mice were depleted with either isotype 
control, CD3, CD4, or CD8 depleting antibodies, and brain and spinal cord tissues were 
harvested on day 5 pi for analysis of viral replication.  While CD3 depletion resulted in a 
significant increase in nsP1 T538I replication in both the brain and spinal cord over isotype 
control depleted, nsP1 T538I infected mice, CD8 depletion also resulted in significantly 
greater nsP1 T538I replication in the spinal cord (Fig. 3.4A and B).  On day 7 pi, when all 
S300 infected mice have succumbed, CD3-depleted and µMT mice displayed comparable 
failure to control nsP1 T538I virus in the CNS on day 7 pi (Fig. 3.4C), while CD3-depleted 
mice display undetectable viral titers at day 15 pi (data not shown).  Similar to µMT mice 
infected with nsP1 T538I, CD3-depleted C57BL/6J mice were capable of recovering from 
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nsP1 T538I infection (data not shown).  Finally, 100% of CD3-depleted mice succumbed to 
S300 infection (data not shown).    
GRKO and GKO mice exhibit markedly different susceptibilities to S300 and 
nsP1 T538I viruses.  One critical effector function of T cells is mediated by IFN-γ, and 
moreover IFN-γ has the unique ability to noncytolytically clear an avirulent strain of SINV 
from persistently infected SCID mice.  Therefore, we investigated the contribution of IFN-γ 
to control and protection during AR86 infection.  Infection of IFN-γ receptor-/- (RGKO) mice 
with either S300 or nsP1 T538I virus was indistinguishable from C57BL/6J matched controls 
as measured by survival, weight loss, or viral replication (Fig. 3.5A-D).   
Despite the lack of a role for the IFN-γ receptor described above, S300 or nsP1 T538I 
infection of mice deficient in IFN-γ cytokine (GKO) resulted in increased survival, with a 
more potent pathogenic role for IFN-γ observed with S300 virus (Fig. 3.6A and B).  
Surprisingly, S300 infected GKO mice behaved similarly to nsP1 T538I infected C57BL/6J 
mice with regard to survival and weight loss.  Prior studies suggest that IFN-γ may exert its 
clearance effect against the TE strain of SINV more potently in the spinal cord than in the 
brain.  To determine if IFN-γ cytokine deficiency affected SINV strain AR86 replication 
within the spinal cord, C57BL/6J and GKO mice were infected with S300 or nsP1 T538I 
viruses.  On day 6 pi, spinal cords were assayed for viral load.  As shown in Figure 3.6C, 
IFN-γ cytokine is dispensable for control of nsP1 T538I infection within the spinal cord.   
To further dissect differences in the response of RGKO to GKO cells to SINV, 
primary astrocytes were isolated from C57BL/6J or the respective knockout neonatal mouse 
brains, and mock infected, IFN-γ treated, or infected with S300 or nsP1 T538I.  This cell type 
was chosen because within the CNS, astrocytes along with microglia are potently activated 
94 
 
by IFN-γ (277).  Total RNA was harvested at 12 hpi and subjected to qRT-PCR, and 
supernatants were analyzed by plaque assay.  Multiple IFN-γ-dependent transcripts were 
quantified.  After S300 infection, expression of Cxcl9 was markedly but equivalently 
decreased from wt levels in astrocytes lacking IFN-γ receptor or cytokine (Fig. 3.6D).  
However, after nsP1 T538I infection, Cxcl9 was significantly increased in GKO astrocytes, 
as compared to either wt or RGKO cells.  Intriguingly, during S300 and nsP1 T538I 
infection, Cxcl10 expression was moderately increased in RGKO compared to wt astrocytes, 
but reached the highest expression level with both viruses in GKO astrocytes.   Cxcl11 
expression was highest in GKO during nsP1 T538I infection.  After S300 infection, both 
RGKO and GKO cells displayed similar Cxcl11 expression, a level that was significantly 
greater than wt cells.  Finally, Nos2 was expressed to significantly greater levels by both 
viruses in RGKO and GKO astrocytes, compared to wt levels (Fig. 3.6D).   
Splenocytes do not require the intrinsic ability to respond to IFN-α/β in order to 
provide control of nsP1 T538I.  Infection of RAG-1-/- mice revealed a critical role for B and 
T cells in mediating control of nsP1 T538I in the CNS.  In addition, we have previously 
shown that the IFN-α/β response is essential for early control of SINV.  Thus, we 
hypothesized that the ability of lymphocytes to respond to type I IFN may contribute to their 
function in clearing nsP1 T538I.  In order to test this hypothesis, we first confirmed that 
transferring wt splenocytes to RAG-1-/- mice prior to infection, and thereby reconstituting a 
nearly intact B and T cell repertoire, would confer control of nsP1 T538I.  Figure 3.2A 
outlines the experimental design, wherein ~2 x 108 splenocytes were transferred to RAG-1-/- 
mice on days -4 and -1 prior to infection.  Mice were infected on day 0 and euthanized on 
day 5 pi in order to harvest tissues for assaying replication and to verify reconstitution by 
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flow cytometry (Fig. 3.7A, Supplemental Fig 3.1).  Indeed, RAG-1-/- mice that were 
reconstituted with wt splenocytes displayed significantly lower levels of nsP1 T538I 
replication as compared to normal RAG-1-/- mice, while S300 replicated similarly in normal 
and reconstituted RAG-1-/- mice (Fig. 3.7B).  Splenocytes deficient in the IFN-α/β receptor 
retained the ability to control nsP1 T538I, thus suggesting this receptor is dispensable on 
lymphocytes during nsP1 T538I infection (Fig. 3.7B).   
The quantity and quality of antibody responses are equivalent between S300 and 
nsP1 T538I.  To investigate the antibody response during S300 and nsP1 T538I infection, 
SINV-specific serum IgG, IgM, IgG1, and IgG2c antibody titers were measured by ELISA.  
C57BL/6 mice do not have the gene for IgG2a, and express the IgG2c isotype instead (216), 
and therefore these studied measured the IgG2c isotype.  All antibody subtypes were 
detectable over mock at day 6 pi, with the exception of IgG1.  However, no differences in 
antibody amounts or neutralization capacity between S300 and nsP1 T538I were observed 
(Fig. 3.8A and B).   
 
3.4 Discussion 
 
The data herein demonstrate that both T and B cells contribute independently and 
additively to recovery and early control of the nsP1 T538I mutant.  However, there is no 
evidence that lymphocytes contribute to S300-induced disease or alter S300 replication.  This 
result, along with our earlier findings suggests that type I IFN and adaptive immunity act in 
combination to drive control of the mutant virus.  Mice lacking either B cells or depleted of T 
cells can recover from nsP1 T538I infection, and do ultimately clear infectious virus from the 
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CNS, suggesting that lymphocytes can compensate in the absence of one cell type, and T and 
B cells possess individual clearance capabilities.  However, the delay in clearance of nsP1 
T538I observed in mice lacking B or T cells reflects an additive interaction between T and B 
cells.  Mice deficient in B and/or T cells do not exhibit more severe disease than wt mice 
after S300 infection, and we report no major effects of T and B cells on the replication of 
S300 in vivo.   Furthermore these studies show that reconstitution of RAG-1-/- mice with wt 
splenocytes confers replication control of nsP1 T538I, independent of intrinsic IFN-α/β 
receptor signaling on splenocytes.   
Both S300 and nsP1 T538I infection induced a similar amount and neutralization 
capacity of SINV-specific antibodies in the serum at 6 dpi.  This result is not surprising, 
because the antigenic load within S300 infected mice is much greater at this time than in 
nsP1 T538I infected mice.  Results with NSV revealed that despite greater levels of 
neutralizing antibody in C57BL/6 mice versus BALB/cBy, 100% mortality was observed in 
C57BL/6 mice and 0% mortality and no neurologic disease was observed in BABL/cBy 
mice.  Moreover, infectious virus was cleared faster in C57BL/6 mice, but viral RNA was 
cleared more slowly (307).  These studies suggest that the amount of neutralizing antibody 
does not necessarily correlate with protection from disease or, in this case, infectious virus. 
Not only do our studies find no evidence for lymphocytes contributing to the 
pathogenesis of S300, they indicate that, similar to avirulent SINV strains, specific 
components of the adaptive immune response are required for the control of the attenuated 
nsP1 T538I mutant within the CNS.  However, similar to NSV, mice lacking the IFN-γ 
cytokine displayed ameliorated disease phenotypes after S300 or nsP1 T538I infection.  To 
our knowledge, GRKO mice have not been evaluated during NSV infection.   
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Studies with NSV demonstrated a pathogenic role for β2-microglobulin and TAP-1-/- 
mice, which lack class I MHC molecules, but not CD8 T cell deficient mice (152).  Both β2-
microglobulin and TAP-1 are up regulated in response to IFN-γ (reviewed in (277)), however 
the mechanism by which class I MHC enhances SINV mortality has yet to be elucidated.  It 
will be informative to determine the role of class I MHC during AR86 infection, and whether 
class I MHC regulates IFN-γ expression or activity.  Moreover, the mechanism by which 
IFN-γ exacerbates neurologic disease, which has now been reported with NSV and AR86 
SINV, is not known.   
The different phenotypes observed between RGKO and GKO mice on the same 
genetic background have been reported previously with herpes-simples virus-1 (HSV-1) and 
vaccinia virus (40), and  discrepancies in the phenotype between receptor and ligand 
deficient mice have also been reported in the literature (62, 228).    After HSV-1 and vaccinia 
virus infection, mortality was significantly increased in RGKO mice compared to GKO mice, 
however in neither case was IFN-γ pathogenic.  One possible explanation for these 
differences is that another, possibly CNS-specific ligand for the IFN-γ receptor exists.  If this 
were true, then this ligand might elicit a different response than IFN-γ itself, but its effect is 
only observed in the absence of IFN-γ. One candidate is Galectin-3, which activates STAT1, 
STAT3, STAT5, and JAK in primary glial cells in an IFN-γ receptor-dependent manner 
(140).   
We hypothesized that the different phenotypes observed in RGKO and GKO mice 
infected with SINV might be reflected by differences in gene expression.  We chose to 
simplify the complex CNS environment by infecting primary astroctyes in vitro, and then 
analyzing IFN-γ dependent genes.  Of the genes analyzed in this study, the most relevant 
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differences are in genes that are differentially expressed between RGKO and GKO, and 
between C57BL/6J and GKO astrocytes, and also that expression differences follow the same 
trend with S300 and nsP1 T538I.  Among the transcripts analyzed, Cxcl10 expression fits 
these requirements, and is more highly expressed in GKO cells infected with S300 and nsP1 
T538I, than in RGKO or C57BL/6J astrocytes infected with the respective viruses.    
We report here that the adaptive immune response regulates nsP1 T538I disease, but 
not S300.  This result combined with previous studies demonstrating that nsP1 T538I 
activates type I IFN and fails to antagonize type I IFN as compared to of S300, suggest that 
type I IFN is stimulating the adaptive immune response.  However, we found no evidence 
that the IFN-α/β receptor signaling on lymphocytes is required for control of viral replication.  
However, these studies do not rule out a direct role for IFN-α/β signaling on T and B cells in 
regulating the development of the adaptive immune response, or more specific functions such 
as cross presentation.  Previous studies have demonstrated that IFN-α/β signaling on both B 
and T cells contributed to the potency of the antibody response (179) and to the development 
of CD8+ T cells during LCMV infection (163).  Future studies should test whether the 
adaptive immune response is stimulated by the type I IFN receptor on candidate cell 
population such as DCs, neurons, and astrocytes.   
In sum, the data presented in these studies demonstrate that both B and T cells 
contribute to recovery and replication control after infection of mice with the nsP1 T538I 
virus, but do not modulate S300 pathogenesis.  Furthermore, the IFN-γ receptor is not 
required for control of replication or recovery during nsP1 T538I infection. However, the 
IFN-γ cytokine exacerbates disease during S300 and nsP1 T538I infection, and is not 
required for control of nsP1 T538I replication.  These studies along with results during 
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neurovirulent infection with NSV suggest that the adaptive immune response may be both 
protective and pathogenic, and that the role of IFN-γ during SINV infection warrants further 
investigation.   
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Figure 3.1:  There is no difference in CNS inflammatory infiltrate after S300 or nsP1 
T538I infection.   
A)      B) 
 
C)      D) 
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Figure 3.1:  There is no difference in the CNS inflammatory infiltrate after S300 or 
nsP1 T538I infection.  Adult 9-12-week-old female C57BL/6J mice were infected i.c. with 
103 PFU of S300 or nsP1 T538I.  On day 5 pi mice were perfused with PBS and CNS 
leukocytes were isolated and stained for various cell surface markers and analyzed by flow 
cytometry.  Data are presented as the means ± the standard deviation, include 3-5 mice per 
group, and are representative of 3 independent experiments.   
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Figure 3.2:  RAG-1-/- mice succumb to nsP1 T538I infection and fail to control nsP1 
T538I replication in the CNS. 
A) 
 
B) 
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Figure 3.2:  RAG-1-/- mice succumb to nsP1 T538I infection and fail to control nsP1 
T538I replication in the CNS. Adult 9-12-week-old female RAG-1-/- or C57BL/6J mice 
were infected i.c. with 103 PFU of S300 or nsP1 T538I virus and monitored daily for (A) 
survival, (B) weight loss, and (C) brain and (D) spinal cords were harvested at 1, 3, and 5 
days post infection for viral titer by plaque assay.  Survival data are presented as the pooled 
results of two experiments.   Weight loss data are presented as the means + standard 
deviations from three experiments.  Viral titer data are shown as the mean and are 
representative of at least three experiments.  The number of mice infected per virus is 
indicated in parentheses.  Asterisks denote p < 0.05(*), p < 0.01(**), p < 0.001(***), or p < 
0.0001(****).  The horizontal dashed line indicates the lower limit of assay sensitivity.   
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Figure 3.3:  µMT mice are capable of recovering from nsP1 T538I infection, yet µMT 
exhibit a defect in control of nsP1 T538I replication in the CNS.    
A) 
 
B) 
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Figure 3.3:  µMT mice are capable of recovering from nsP1 T538I infection, yet µMT 
exhibit a defect in control of nsP1 T538I replication in the CNS.   Adult 9-12-week-old 
female µMT or C57BL/6J and mice were infected i.c. with 103 PFU of S300 or nsP1 T538I 
virus. (A) Survival and (B) weight loss of S300 and nsP1 T538I infected C57BL/6J or µMT 
mice as indicated.  The number of mice infected per group is indicated in parentheses.  
Infectious virus was assayed at 5 days pi in the (C) brain and (D) spinal cord.  Asterisks 
denote p < 0.01(**).  Titer data are representative of two or more experiments.  The dashed 
line indicates the lower limit of assay sensitivity.    
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Figure 3.4:  T cells contribute to control of the nsP1 T538I virus. 
A)     B) 
 
C)     D) 
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Figure 3.4:  T cells contribute to control of the nsP1 T538I virus. Adult 9-12-week-old 
female C57BL/6J were depleted of total T cells or T cells subsets, and mice were infected i.c. 
with 103 PFU of S300 or nsP1 T538I virus.  Infectious virus was assayed at 5 dpi in the (A) 
brain and (B) spinal cord.  (C, D) For surviving nsP1 T538I infected animals, infectious virus 
was assayed at 7 dpi and compared to µMT tissues.  Asterisks denote p < 0.05(*), p < 
0.01(**), p < 0.001(***), or p < 0.0001(****).  Titer data are representative of two or more 
experiments.  The dashed line indicates the lower limit of assay sensitivity.    
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Figure 3.5:  IFN-γ signaling is not required for protection from disease or control of the 
nsP1 T538I virus. 
A) 
 
B) 
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Figure 3.5:  IFN-γ signaling is not required for protection from disease or control of the 
nsP1 T538I virus.  Adult 9-12-week-old female C57BL/6J or RGKO mice were infected i.c. 
with 103 PFU of S300 or nsP1 T538I virus.  (A) Survival and (B) weight loss of S300 and 
nsP1 T538I infected C57BL/6J or RGKO mice as indicated. Infectious virus was assayed at 5 
dpi in the (A) brain and (B) spinal cord.  Asterisks denote p < 0.01(**), p < 0.001(***), or p 
< 0.0001(****).  Titer data are representative of two or more experiments.  The dashed line 
indicates the lower limit of assay sensitivity. 
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Figure 3.6:  IFN-γ cytokine is pathogenic during SINV infection. 
A) 
 
B) 
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Figure 3.6:  IFN-γ cytokine is pathogenic during SINV infection. Adult 9-12-week-old 
female C57BL/6J or GKO mice were infected i.c. with 103 PFU of S300 or nsP1 T538I 
virus.  (A) Survival and (B) weight loss of S300 and nsP1 T538I infected C57BL/6J or GKO 
mice as indicated. Infectious virus was assayed at 5 dpi in the (C) spinal cord.  (Asterisks 
denote p<0.01(**), p<0.001(***), or p<0.0001(****).  Titer data are representative of two or 
more experiments.  The dashed line indicates the lower limit of assay sensitivity.   (D)  
Relative expression of the IFN-γ dependent genes Cxcl9, Cxcl10, Cxcl11, and Nos2 in 
primary murine astrocytes infected with S300, nsP1 T538I, or treated with IFN-γ.  
Quantitative real-time PCR was performed in triplicate and raw data values were normalized 
to GAPDH rRNA levels and shown above as fold expression over mock-infected astrocytes.  
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Figure 3.7:  Expression of the IFN α/β receptor on splenocytes is not required for 
control of nsP1 T538I.   
A) 
 
B) 
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Figure 3.7:  Expression of the IFN α/β receptor on splenocytes is not required for 
control of nsP1 T538I.  (A)  Schematic timeline of reconstitution experimental design.  
Adult 9-12-week-old female RAG-1-/- mice were infected i.c. with 103 PFU of S300 or nsP1 
T538I Infectious virus was assayed at 5 days pi in the (B) brain.  Asterisks denote p < 
0.001(***).  Titer data are pooled from 3 experiments.  The dashed line indicates the lower 
limit of assay sensitivity.  
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Figure 3.8:  No differences in quantity or quality of serum antibody responses after 
S300 or nsP1 T538I infection.   
A)      
 
 B) 
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Figure 3.8:  No differences in quantity or quality of serum antibody responses after 
S300 or nsP1 T538I infection.  Adult 9-12-week-old female µMT or C57BL/6J and mice 
were infected i.c. with 103 PFU of S300 or nsP1 T538I virus. (A) Serum SINV-specific 
antibody and (B) PRNT50 neutralization titers are depicted.  Mock infected serum is reported 
as a negative control.   
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Supplemental Figure 3.1:  Representative quantification of CD3, CD4, CD8, and isotype 
control depleted mice.   
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Supplemental Figure 3.1:  Representative quantification of CD3, CD4, CD8, and isotype 
control depleted mice.  Adult female C57BL/6J mice were treated with depleting antibodies 
1 day prior to i.c. infection, 24 hpi, and 96 hpi.  On day 5 pi, spleens were harvested and 
analyzed by flow cytometry to quantify T cell populations and very depletions.   
 CHAPTER FOUR: 
 
DISCUSSION 
 
4.1 Type I IFN limits SINV replication and spread 
 
The type I IFN response is well-established as being the most critical component of 
innate immunity during alphavirus infection and many other viral infections.  Indeed, mice 
lacking the IFN-α/β receptor exhibit uncontrolled alphavirus replication, marked by enhanced 
tissue tropism, and even avirulent alphaviruses cause uniformly rapid mortality in these mice.    
The studies herein further our understanding of innate immune recognition of the 
neurovirulent AR86 strain of SINV.  Specifically, we identify IPS-1 and TRIF-dependent 
signaling as having anti-SINV properties, and we suggest differences in the antiviral roles of 
these two pathways.  These studies demonstrate that IPS-1 does not mediate all of the 
protection conferred by type I IFN, thereby leading us to speculate contributory roles for 
multiple innate immune sensing pathways and the importance of IFN signaling to control of 
AR86.   
The studies presented here provide a thorough examination of the adaptive immune 
components that drive resolution of viral infection or exacerbate disease.  We show 
individual contributions of T and B cells to protection from disease and promotion of viral 
clearance, while we also demonstrate contradictory roles for the IFN-γ receptor and cytokine 
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during SINV infection.  Furthermore, we advance our understanding of how type I IFN 
initiates the development of the adaptive immune response.     
 
4.2 Direct antiviral effect of ISGs during AR86 infection 
 
Our data strongly argue that IPS-1-dependent signaling plays a major role in 
modulating AR86 neurovirulence.  Since IPS-1 is critical in mediating the activation of type I 
IFN and the subsequent upregulation of hundreds of ISGs, we are especially interested in 
understanding if infection with the nsP1 T538I mutant virus results in increased expression 
or activity of ISGs compared to S300 infection, and if this process is dependent on IPS-1.  
Candidate ISGs that have previously been shown to possess anti-SINV activity against 
different strains of SINV include ISG15, Viperin, ZAP, and PKR (discussed in detail in 
Chapter One).  However, exhaustive expression analysis comparing S300 and nsP1 T538I 
infected CNS regions did not reveal any major differences in expression of a large panel of 
ISGs (data not shown).  Furthermore, ISG15-/- mice were able to control nsP1 T538I virus 
replication equivalently to age-matched C57BL/6J controls (data not shown).     
As we continued to search for ISGs that mediate anti-viral activity against nsP1 
T538I, we hypothesized a role for IFIT family members, which are strongly induced by type 
I IFN.  The three IFITs: IFIT1, IFIT2, and IFIT3 form a complex that binds 5’ triphosphates 
on uncapped viral RNA.  Although alphavirus RNA is capped by nsP1 and nsP2 in the 
cytoplasm, we have evidence that uncapped viral RNA may be present within cells infected 
with an RRV mutant that is similar to nsP1 T538I (C. Cruz, unpublished results).  In addition 
to binding RNA, IFIT1 binds the translation initiation factor eIF3, resulting in inhibition of 
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host translation initiation (323).  We hypothesized that IFIT family members may contribute 
to control of nsP1 T538I replication.  To test this hypothesis we mock treated or IFN-β 
treated wild type, Ifit1-/-, Ifit2-/-, and Ifit locus-/- (all three IFITs are deleted) mouse embryonic 
fibroblasts (MEFs) (generated in the Sen Laboratory), followed by infection with nsP1 
T538I.  We observed no difference in viral replication in wild type or Ifit deficient MEFs that 
had not been pretreated with IFN-β, with the exception of an early 8 hpi replication 
advantage of nsP1 T538I within Ifit locus-/- untreated MEFs (Fig 4.1A-C).  However, if the 
MEFs were primed with IFN-β prior to infection, Ifit1-/-, Ifit2-/-, and Ifit locus-/- MEFs 
supported significantly greater amounts of viral replication.  Ifit1-/- MEFs exhibited 
significantly higher replication beginning at 9 hpi and continuing through 24 hpi, while Ifit2-/- 
MEFs supported significantly higher replication at 12 hpi and later time points through 24 
hpi (Fig 4.1A and B).  Finally, Ifit locus-/- MEFs primed with IFN-β also supported 
significantly enhanced nsP1 T538I replication between 8 and 24 hpi (Fig 4.1C).   
These initial observations are the first example of potent IFIT antiviral activity during 
SINV infection, and moreover these studies differ from observations with SINV strain 
TR339.  In vitro over-expression and knockdown studies using TR339 infection showed no 
role for IFIT2 and a modest role for IFIT1 (350).  It is possible that levels of siRNA 
knockdown may not have been complete, or the results with AR86 and TR339 may represent 
fundamental strain differences in host-viral interactions.   
Interestingly, both RLRs and IFITs recognize free 5’ triphosphates, which we 
hypothesize are exclusively present and/or accessible in nsP1 T538I infected cells.  
Furthermore, IFIT3 and IPS-1 interact with tumor necrosis factor receptor (TNFR)-
associated factor (TRAF) family member-associated NF-κB activator-binding kinase 
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(TBK1), and the interaction between IFIT3 and TBK1 contributes to IRF3 activation (192).  
Our independent findings that IPS-1 and IFITs possess anti-SINV activity suggest that IPS-1 
and IFITs may cooperate in SINV infected cells to activate IRF3 and type I IFN.   
 
4.3 IPS-1 does not mediate all of the protection conferred by type I IFN 
 
 We describe here that i.c. infected IPS-1-/- mice do not die as quickly as Ifnar-/- mice 
and replication in the CNS is lower in IPS-1-/- mice than Ifnar-/- mice.  Similarly, footpad 
infected 28 day-old IPS-1-/- mice did not die as quickly as control infected Ifnar-/- mice (Fig. 
4.2A and B).  Interestingly, adult Ifnar-/- mice remain highly susceptible to footpad infection 
with nsP1 T538I, while footpad infection of nsP1 T538I does not cause neurologic disease or 
death in adult IPS-1-/- mice (data not shown).  This latter result suggests that IPS-1 is 
especially critical within the CNS of adult mice, and not as critical within the periphery.  
These results are not surprising, considering that loss of the IFN-α/β receptor abrogates all 
cellular responses to type I IFN, however loss of IPS-1 only abrogates one of multiple host 
sensing pathways.   
Ifnar-/- mice produce extremely high amounts of serum type I IFN in response to 
AR86 infection (Fig, 4.3A), likely due to a lack of negative feedback and/or uncontrolled 
replication.  Serum IFN is equivalent in wild-type and IPS-1-/- nsP1 T538I infected mice, and 
CNS expression of ISG transcripts is increased in IPS-1-/- mice at late time post-infection 
(Fig. 4.3A and data not shown).  In primary cell culture, IPS-1-/- bone marrow-derived 
macrophages, dendritic cells, and astrocytes fail to produce detectable type I IFN after 
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infection with nsP1 T538I, while TRIF-/- astrocytes display a defect in IFN production (Fig. 
4.3B-D).   
Our finding that IPS-1 mice do not recapitulate the extreme susceptibility of Ifnar-/- 
mice to AR86 has two likely possibilities:  (1) another induction pathway contributes to IFN 
production during AR86 infection or (2) type I IFN signaling is responsible for limiting 
AR86 replication and limiting neurologic disease after AR86 infection.  To address the first 
hypothesis, future studies should evaluate mice deficient in two and three adaptor genes.   
To begin to address the second hypothesis, we tested whether CNS specific induction 
of IFN-β differed after S300 or nsP1 T538I infection in vivo.  To determine IFN-β expression 
at the cellular level, we infected a bicistronic YFP-reporter mouse termed IFNβmob/mob (272) 
with 103 PFU of S300, nsP1 T538I, or mock-infected.  At 24 hpi, brains were fixed overnight 
in 4% PFA, incubated in 30% sucrose for 24 h, and frozen in Tissue-Tek OCT Compound at 
-80˚C.  Brains were sectioned at 10 µm with a cryostat and mounted on poly-L-lysine-coated 
slides prior to staining with anti-NeuN (neuronal nuclei, clone A60: Chemicon), anti-GFP 
(ab6556-25; Abcam), and DAPI.  Examination of sections using a Nikon FXA microscope 
and ImageJ software revealed specific and potent IFN-β expression after infection with S300 
or nsP1 T538I within neurons of the hippocampus (Fig. 4.4) and cerebellum (data not 
shown).  Importantly, these preliminary results reveal no apparent differences in early IFN-β 
expression in the CNS of S300 and nsP1 T538I infected brains.  However, future studies are 
critical to determine if temporal or localization differences exist in IFN-β expression within 
S300 and nsP1 T538I infected brains.   
Thus, the lack of difference in CNS-specific IFN-β induction between S300 and nsP1 
T538I suggests that a downstream effect of type I IFN may be responsible for the attenuation 
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of nsP1 T538I in vivo.  To determine if IFN signaling is modulating nsP1 T538I, future 
studies should evaluate if IRF7 or IRF7/IPS-1 deficient mice exhibit equivalent susceptibility 
to AR86 as compared to Ifnar-/- mice.  IRF7 is an essential transcription factor required for 
the amplification of IFN signaling,   
Future studies should also address which cell types exert the protective effect of IFN, 
and which cell types required IPS-1 for the production of type I IFN.  One way to address 
these questions would be to use the cyclization recombination (Cre-Lox) system to derive 
mice with cell type specific deletions in Ifnar or IPS-1.  By directly comparing IPS-1 and 
Ifnar cell type specific deficiencies, one could begin to delineate the cell types responsible 
for the induction and subsequent response to type I IFN.  Prinz et al. crossed mice expressing 
loxP-flanked Ifnar to mice expressing Cre recombinase under the control of promoters 
specific to brain neuroectoderm-derived CNS cells (astrocytes, oligodendrocytes, and 
neurons), or CD11b+ cells (microglia and monocytes) (247).  Intriguingly CNS-specific Ifnar 
expression is critical for limiting VSV replication in the brain, despite the presence of normal 
levels of serum IFN, neutralizing antibody, and clearance of virus from the periphery (65).   
 
4.4 The adaptive immune response modulates SINV 
 
Because the nsP1 T538I is cleared more efficiently from the CNS than S300 virus, 
and only nsP1 T538I infected mice are capable of recovery, we tested the role of adaptive 
immunity during AR86 infection.  We describe here independent and additive roles for B and 
T cells during nsP1 T538I infection, but no role for lymphocytes during S300 infection.  
While the IFN-γ receptor plays no detectable role during AR86 infection, the IFN-γ cytokine 
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exacerbates disease and increases mortality following S300 or nsP1 T538I infection.  The 
finding that adaptive immunity serves a protective role during nsP1 T538I, but not S300 
infection, in combination with previous studies demonstrating that nsP1 T538I more potently 
activates the innate immune response, suggests a possible synergy between innate and 
adaptive immune pathways.  Therefore, we tested whether unprimed T and B cells require 
the type I IFN receptor to drive clearance of nsP1 T538I.  Our results suggest that the type I 
IFN response does not need to occur within T and B cells to mediate the clearance process, 
however future studies are required to rule out this possibility.  Such future studies could use 
the Cre-Lox breeding scheme as described above to generate mice with an inducible deletion 
of the type I IFN receptor in a tissue or cell specific manner.  To circumvent issues such as 
embryonic lethality and development defects caused by gene knockouts, ligand-dependent 
Cre recombinases can be engineered, whereby Cre is fused to an inactive hormone-binding 
domain of the estrogen receptor (CreER).  The CreER recombinases can be activated by 
treating mice with a synthetic estrogen receptor ligand (166).   
Another approach to investigate cell-specific roles for type I IFN would be to 
generate bone marrow chimaeric mice which possess T or B cells lacking the type I IFN 
receptor.  Specifically, µMT mice should be irradiated and reconstituted with a mixture of 
bone marrow from µMT mice and Ifnar-/- mice, according to (179).  To determine if IFN-α/β 
signaling on T cells contributes to their antiviral activity during SINV infection, T cell 
deficient Tcrb-/-Tcrd-/- mice should be irradiated and reconstituted with a mixture of bone 
marrow from Tcrb-/-Tcrd-/- mice and Ifnar-/- mice.  µMT and Tcrb-/-Tcrd-/- mice should be 
used in these respective studies because radiation-resistant T and B cells exist that could 
complicate interpretation of the results (Personal communication, David Tough).   
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4.5 Contradictory phenotypes in IFN-γ receptor and cytokine deficient mice 
 
Simmons et. al  demonstrated that the Thr virulence determinant at nsP1 position 538 
is required for early inhibition of the Jak/STAT signaling pathway in response to type I or II 
IFN (289).  This data revealed that neurovirulence correlated with Jak/STAT inhibition, and 
led us to hypothesize that IFN-γ signaling may modulate the clearance phenotype observed in 
nsP1 T538I infected mice.  Surprisingly, GRKO mice were as efficient as wild-type mice in 
controlling nsP1 T538I replication in the CNS and limiting neurologic disease.  However, 
GKO mice showed ameliorated disease and reduced mortality after infection with S300 or 
nsP1 T538I.  Moreover, both S300 and nsP1 T538I infectious virus was undetectable at 6 dpi 
within the spinal cord, suggesting the possibility that an IFN-γ independent pathway is 
responsible for viral clearance.   
In order to first confirm these different phenotypes we observed in GKO and GRKO 
mice, one could deplete C57BL/6J mice with IFN-γ receptor or IFN-γ depleting antibodies, 
followed by infection with SINV.  If indeed the results are repeated, then future studies could 
investigate the mechanism of IFN-γ dependent pathogenesis.  Studies should investigate the 
accumulation, localization, and effector function of T cells and NK cell in wild type and 
GKO mice infected with AR86.     
Preliminary studies showed that the IFN-γ inducible chemokine, CXCL10 expression 
was highest in GKO primary astrocytes infected with AR86 as compared to GRKO or wild 
type astrocytes.  Interestingly, CXCL10 has been shown to play a protective role by 
recruiting CD8+ T cells during West Nile infection and dengue virus infection (50, 155).  
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Therefore it will be interesting to determine if the CXCL10 receptor (CXCR3) or CXCL10 
play a protective role during AR86 infection.   
 
4.6 Conclusions 
 
The goals of this dissertation were to determine the contributions of innate and 
adaptive immune pathways to protection from AR86 neurologic disease.  By directly 
comparing wild type S300 to the attenuated nsP1 T538I virus in the context of different 
knockout mice, we were able to more clearly define the role of specific host pathways in 
regulating innate control of the nsP1 T538I mutant as well as the role of specific aspects of 
the adaptive immune response in mediating viral control.  Though we were not able to 
establish a direct link between the type I IFN system and the adaptive immune response in 
mediating the control of the nsP1 T538I virus, it is clear that the two pathways are both 
essential for effective control of the mutant virus. 
These studies identify the RLR intracellular sensing pathway as being critical in 
eliciting protection and controlling viral replication during infection with nsP1 T538I.  To 
our knowledge, this study represents the first to identify a protective role for IPS-1 during 
neurovirulent alphavirus infection.  In addition, we demonstrate that the TLR3-dependent 
TRIF pathway plays an intermediate role in protection from AR86 neurologic disease.   
Finally, we report preliminary results that IFITs possess antiviral activity against 
AR86.  Both RLRs and IFITs recognize free 5’ triphosphates, which we hypothesize are 
exclusively present and/or accessible in nsP1 T538I infected cells.  Thus, an exciting new 
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avenue of research now exists to determine if IPS-1 and IFIT interplay mediate protection 
from SINV-induced neurologic disease.    
These studies establish fundamental differences in the role of adaptive immunity 
following S300 and nsP1 T538I infections.  We show that adaptive immunity is essential in 
mediating protection during nsP1 T538I infection, but not important during S300 infection.  
We further demonstrate that expression of the type I IFN receptor on lymphocytes is not 
essential to their role in replication control.   
We hypothesized that, based on in vitro results that IFN-γ would serve a protective 
role during nsP1 T538I infection.  However, IFN-γ receptor deficient mice were 
indistinguishable from wild type mice infected with S300 or nsP1 T538I.  Remarkably, IFN-
γ cytokine deficient mice were less susceptible to infection with both viruses.  Future studies 
should directly confirm and further dissect the mechanism that explains this difference and 
the IFN-γ dependent enhancement of disease.   
In sum, these studies have provided new insights into host pathways involved in 
recognition and elimination of a neurovirulent SINV.  We have identified the key molecules 
that modulate SINV infection during the innate and adaptive stages of immunity, and we 
explore mechanisms that bridge the two stages.  The data herein implicate that IFN-γ, widely 
considered the critical mediator of noncytolytic neuronal clearance, can serve a pathogenic 
role in certain contexts.  These studies provide a framework that will aid further investigation 
into the dynamics of intracellular sensing of SINV, the synergy of ISGs, and the development 
of the adaptive immune response.   
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Figure 4.1:  IFITs inhibit nsP1 T538I replication in IFN-β pretreated MEFs.   
A) 
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Figure 4.1:  IFITs inhibit nsP1 T538I in IFN-β pretreated MEFs.  (A-C) Wild type, (A) 
IFIT1-/-, (B) IFIT2-/-, and (C) IFIT locus-/- mouse embryonic fibroblasts were either untreated 
or treated with 100 U murine IFN-β 12 hours prior to infection (MOI 1) with the attenuated 
mutant Sindbis virus nsP1 T538I.  Viral replication was measured by standard plaque assay 
on BHK-21 cells.  Samples were analyzed in triplicate and error bars represent the standard 
deviation.  Data were analyzed by Two-way ANOVA.   
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Figure 4.2:  Ifnar-/- and IPS-1-/- mice are more susceptible than C57BL/6J mice to nsP1 
T538I peripheral infection.   
A) 
 
B) 
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Figure 4.2:  Ifnar-/- and IPS-1-/- mice are more susceptible than C57BL/6J mice to nsP1 
T538I peripheral infection.  28 day-old C57BL/6J, (A) Ifnar-/-, and (B) IPS-1-/- mice were 
infected in the left rear footpad with 103 PFU of nsP1 T538I and monitored daily for 
survival.   
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Figure 4.3:  IPS-1 is required for type I IFN production in primary murine cells, but 
not in serum.   
A) 
 
B) 
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Figure 4.3:  IPS-1 is required for type I IFN production in primary murine cells.   
(A) Adult 9-12 week-old C57BL/6J, IPS-1-/-, and Ifnar-/- mice were infected i.c. with 103 
PFU of nsP1 T538I and serum was collected at 18 hpi, and assayed by bioassay for type I 
IFN.  (B-D) Primary murine cells were isolated and purified as described previously (141, 
282).  C57BL/6J and IPS-1-/- bone-marrow derived (B) macrophages and (C) DCs were 
infected with nsP1 T538I (MOI 5), and supernatants were harvested at 18 hpi and assayed for 
type I IFN by IFN bioassay.  (D)  C57BL/6J, IPS-1-/-, and TRIF-/- primary astrocytes were 
infected with nsP1 T538I (MOI 5), and supernatants were harvested at 12 and 18 hpi and 
assayed by IFN bioassay for type I IFN.  Samples were analyzed in triplicate and error bars 
represent standard deviation.  Statistical tests performed were (B, C) two-way ANOVA, and 
(D) one-Way ANOVA.   
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Figure 4.4:  Neurons express IFN-β within AR86 infected brains.   
A) 
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Figure 4.4:  IFN-β is primarily induced within neurons in AR86 infected brains.  (A)  
Shown is the localization of IFN-β/YFP+ cells in the hippocampi at 24 h after i.c. infection 
with 103 PFU of S300 or nsP1 T538I.  YFP+ cells were detected by using a cross-reacting 
polyclonal α-GFP antibody (ab6556-25; Abcam).  Signals were amplified with tyramide-
FITC for YFP (PerkinElmer).  Mock nuclei were stained with DAPI.  Neurons were detected 
by using anti-NeuN (neuronal nuclei, clone A60; Chemicon), followed by biotinylated anti-
Rabbit immunoglobulin G, and Texas Red-labeled avidin preparations.   
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